

OM of: US-09-439-311-2 to: Issued\_Patents\_NA:\* out\_format : pfs  
Date: Apr 17, 2002 3:10 AM

About: Results were produced by the GenCore software, version 4.5,  
Copyright (c) 1993-2000 Compugen Ltd.

## Command line parameters:

```
-MODE=frame+27n model -DEV=xlp  
-O=/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-358-972-102  
-DB=Issued_Patents_NA -QFMT=fastip -SUFFIX=trn1 -GAPOP=12.000  
-GAPEXT=4.000 -MINMATCH=0.100 -XGAPOP=10.000 -XGAPEXT=0.000  
-GAPOP=6.000 -GAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500  
-DELOP=6.000 -DELEXT=7.000 -START=1 -MATRIX=blonsum62  
-TRANS=human40.cdi -LIST=45 -DOCALLIGN=200 -THR_SCORE=pcr  
-THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pfs  
-NORMEXT -MINLEN=0 -MAXLEN=60 -USER=US09439311.ecgnt1_1.77  
-NCPU=6 -ICPU=3 -LONGLOG -NO_XLPXY -WAIT -THREADS=1
```

## Search information block:

```
Query: US-09-439-311-2  
Query length: 333  
Database: Issued_Patents_NA:*  
Database sequences: 351203  
Database length: 11323899  
Search time (sec): 85.700000
```

## Score\_list:

Sequence	Strd Orig	ZScore	EScore	Len	Documentation
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-358-972-102				50.00	116.12 80.95
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-358-972-103				50.00	116.12 80.95
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-406-147-32				50.00	116.12 80.95
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-406-147-33				50.00	116.12 80.95
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-130-663-22				43.00	96.03 1.1e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-180-29				43.00	96.03 1.1e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-040-786-29				43.00	96.03 1.1e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-432-335-22				43.00	96.03 1.1e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-219-012-80				40.00	88.19 2.9e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-687-421-268				40.00	88.19 2.9e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-482-882-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-389-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-487-113D-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-473-503-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-483-932-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-714-017-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-475-680-97				39.00	89.11 2.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-537-357-46				38.00	87.66 3.1e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-353-657-3				38.00	85.71 4.0e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-709-982-3				38.00	85.71 4.0e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-982-865-3				38.00	85.71 4.0e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-587-209-6				37.00	93.14 1.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-689-236-6				37.00	93.14 1.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-689-235-6				37.00	93.14 1.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-692-726-6				37.00	93.14 1.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-813-507-82				37.00	86.79 3.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-109-063-28				37.00	84.67 4.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-975-699-4				37.00	82.27 6.2e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-972-089-4				37.00	82.27 6.2e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-766-354A-15				37.00	82.27 6.2e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-133-711-5				36.50	81.89 6.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-158-863C-5				36.50	81.89 6.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-675-566-100				36.50	81.89 6.5e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-564-955-51				36.00	81.77 6.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-537-874-54				36.00	81.77 6.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-08-621-859-54				36.00	81.77 6.6e+03
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-100-856A-54				36.00	81.77 6.6e+03

```
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-075-511-54 + 36.00 81.77 6.6e+03 53  
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-099-015-54 + 36.00 81.77 6.6e+03 53  
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-232-863-54 + 36.00 81.77 6.6e+03 53  
/cgn2_6/prodata/2/lna/6B_COMB.seq:US-09-133-508A-54 + 36.00 81.77 6.6e+03 53
```

## seq\_name: /cgn2\_6/prodata/2/lna/6B\_COMB.seq:US-09-358-972-102

seq\_documentation\_block:

Sequence 102, Application US/09358972

Patent No. 6235480

GENERAL INFORMATION:

APPLICANT: Shultz, John W.

APPLICANT: Lewis, Martin K.

APPLICANT: Lieppe, Donna

APPLICANT: Mandrekar, Michelle

APPLICANT: Kephart, Daniel

APPLICANT: Rhodes, Richard B.

APPLICANT: Andrews, Christine A.

APPLICANT: Hartnett, James R.

APPLICANT: Olson, Ryan J.

APPLICANT: Wood, Keith W.

TITLE OF INVENTION: Nucleic Acid Detection

FILE REFERENCE: Pro-103 6868/75528

CURRENT APPLICATION NUMBER: US/09/358,972

EARLIER FILING DATE: 1999-07-22

EARLIER APPLICATION NUMBER: 09/252,436

EARLIER FILING DATE: 1999-02-18

EARLIER APPLICATION NUMBER: 09/042,287

NUMBER OF SEQ ID NOS: 290

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 102

LENGTH: 30

TYPE: DNA

ORGANISM: Campylobacter jejuni

OTHER INFORMATION: probe to Campylobacter jejuni

US-09-358-972-102

## alignment\_scores:

Quality: 50.00

Ratio: 5.000

Percent Similarity: 100.000

Percent Identity: 100.000

## alignment\_block:

US-09-439-311-2 x US-09-358-972-102/rev ..

Align seg 1/1 to reverse of: US-09-358-972-102 from: 1 to: 30

97 GlnasgIyGlnserLeuIyThraArgThr 106

|||||

30 CAAGATGACAAAGTTTAAAAACAAGAACT 1

seq\_name: /cgn2\_6/prodata/2/lna/6B\_COMB.seq:US-09-358-972-103

seq\_documentation\_block:

Sequence 103, Application US/09358972

Patent No. 6235480

GENERAL INFORMATION:

APPLICANT: Shultz, John W.

APPLICANT: Lewis, Martin K.

APPLICANT: Lieppe, Donna

APPLICANT: Mandrekar, Michelle

APPLICANT: Kephart, Daniel

APPLICANT: Rhodes, Richard B.

APPLICANT: Andrews, Christine A.

APPLICANT: Hartnett, James R.

APPLICANT: Olson, Ryan J.

APPLICANT: Wood, Keith W.

```
; APPLICANT: Welch, Roy
; TITLE OF INVENTION: Nucleic Acid Detection
; FILE REFERENCE: Pro-103 6868/75528
; CURRENT APPLICATION NUMBER: US/09/358,972
; CURRENT FILING DATE: 1999-07-22
; EARLIER APPLICATION NUMBER: 09/252,436
; EARLIER FILING DATE: 1999-02-18
; EARLIER APPLICATION NUMBER: 09/042,287
; EARLIER FILING DATE: 1998-03-13
; NUMBER OF SEQ ID NOS: 290
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 103
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Campylobacter jejuni
; FEATURE:
; OTHER INFORMATION: probe to Campylobacter jejuni
US-09-358-972-103
```

```
alignment_scores:
  Quality: 50.00      Length: 10
  Ratio: 5.000       Gaps: 0
  Percent Similarity: 100.000  Percent Identity: 100.000
```

```
alignment_block:
US-09-439-311-2 x US-09-358-972-103  ..
Align seg 1/1  to: US-09-358-972-103  from: 1  to: 30
```

```
97 GlnAspGlyGlnSerLeuLysThrArgThr 106
|||||
1 CAAGATGCAACAAAGTTTAAAAACAAGAACT 30
```

```
seq_name: /cgn2_6/prodata/2/lna/6A_COMB.seq:US-09-406-147-32
```

```
seq_documentation_block:
; Sequence 32, Application US/09406147
; Patent No. 6270974
; GENERAL INFORMATION:
; APPLICANT: Shultz, John W
; APPLICANT: Lewis, Martin K
; APPLICANT: Leipzig, Donna
; APPLICANT: Mandrekas, Michelle
; APPLICANT: Kephart, Daniel
; APPLICANT: Rhodes, Richard B
; APPLICANT: Andrews, Christine A
; APPLICANT: Hartnett, James R
; APPLICANT: Gu, Trent
; APPLICANT: Wood, Keith V
; TITLE OF INVENTION: EXOGENOUS NUCLEIC ACID DETECTION
; FILE REFERENCE: EXOGENOUS NUCLEIC ACID DETECTION
; CURRENT APPLICATION NUMBER: US/09/406,147
; CURRENT FILING DATE: 1999-09-27
; EARLIER APPLICATION NUMBER: 09/252,436
; EARLIER FILING DATE: 1999-02-18
; EARLIER APPLICATION NUMBER: 09/042,287
; EARLIER FILING DATE: 1998-03-13
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 32
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Campylobacter jejuni
US-09-406-147-32
```

```
alignment_scores:
  Quality: 50.00      Length: 10
  Ratio: 5.000       Gaps: 0
  Percent Similarity: 100.000  Percent Identity: 100.000
```

```
alignment_block:
US-09-439-311-2 x US-09-406-147-32/rev  ..
Align seg 1/1  to reverse of: US-09-406-147-32  from: 1  to: 30
```

```
97 GlnAspGlyGlnSerLeuLysThrArgThr 106
|||||
30 CAAGATGCAACAAAGTTTAAAAACAAGAACT 1
```

```
seq_name: /cgn2_6/prodata/2/lna/6A_COMB.seq:US-09-406-147-34
```

```
seq_documentation_block:
; Sequence 34, Application US/09406147
; Patent No. 6270974
; GENERAL INFORMATION:
; APPLICANT: Shultz, John W
; APPLICANT: Lewis, Martin K
; APPLICANT: Leipzig, Donna
; APPLICANT: Mandrekas, Michelle
; APPLICANT: Kephart, Daniel
; APPLICANT: Rhodes, Richard B
; APPLICANT: Andrews, Christine A
; APPLICANT: Hartnett, James R
; APPLICANT: Gu, Trent
; APPLICANT: Wood, Keith V
; TITLE OF INVENTION: EXOGENOUS NUCLEIC ACID DETECTION
; FILE REFERENCE: EXOGENOUS NUCLEIC ACID DETECTION
; CURRENT APPLICATION NUMBER: US/09/406,147
; CURRENT FILING DATE: 1999-09-27
; EARLIER APPLICATION NUMBER: 09/252,436
; EARLIER FILING DATE: 1999-02-18
; EARLIER APPLICATION NUMBER: 09/042,287
; EARLIER FILING DATE: 1998-03-13
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 34
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Campylobacter jejuni
US-09-406-147-34
```

```
alignment_scores:
  Quality: 50.00      Length: 10
  Ratio: 5.000       Gaps: 0
  Percent Similarity: 100.000  Percent Identity: 100.000
```

```
alignment_block:
US-09-439-311-2 x US-09-406-147-34  ..
```

```
Align seg 1/1  to: US-09-406-147-34  from: 1  to: 30
```

```
97 GlnAspGlyGlnSerLeuLysThrArgThr 106
|||||
1 CAAGATGCAACAAAGTTTAAAAACAAGAACT 30
```

```
seq_name: /cgn2_6/prodata/2/lna/6A_COMB.seq:US-09-130-663-22
```

```
seq_documentation_block:
; Sequence 22, Application US/09130663A
; Patent No. 6020163
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; TITLE OF INVENTION: LIPOCALIN HOMOLOG
; FILE REFERENCE: 97-24
; CURRENT APPLICATION NUMBER: US/09/130,663A
; CURRENT FILING DATE: 1998-08-05
; EARLIER APPLICATION NUMBER: 60/054,867
; EARLIER FILING DATE: 1997-08-06
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 22
```

LENGTH: 51  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Oligonucleotide primer: ZC13735.  
US-09-130-663-22

Alignment\_scores:  
Quality: 43.00 Length: 16  
Ratio: 3.583 Gaps: 0  
Percent Similarity: 75.000 Percent Identity: 50.000

Alignment\_block:  
US-09-439-311-2 x US-09-130-663-22 ..

Align seg 1/1 to: US-09-130-663-22 from: 1 to: 51

253 GlyValValIleGlyLysValAspTyrSerAspGlyAspGluAsnGly 268  
||||| :||| |||||:||||| |||:|||||  
1 GGTGAACCTTGCACAGAGATTACAGAGCAGTGTGACAGAGGT 48

seq\_name: /cgn2\_6/prodata/2/lna/6A\_COMB.seq:US-09-081-180-29

seq\_documentation\_block:  
Sequence 29, Application US/09081180  
Patent No. 6022847  
GENERAL INFORMATION:  
APPLICANT: Sheppard, Paul O.  
TITLE OF INVENTION: SECRETED SALIVARY ZSIG32  
TITLE OF INVENTION: POLYPEPTIDES  
NUMBER OF SEQUENCES: 38  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Zymogenetics  
STREET: 1201 Eastlake Ave. E.  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98102  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/081,180  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/041,263  
FILING DATE: March 19, 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Lingenfelter, Susan E  
REGISTRATION NUMBER: 41,156  
REFERENCE/DOCKET NUMBER: 97-17C1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-442-6675  
TELEFAX: 206-442-6678  
TELEX:  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 51 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
IMMEDIATE SOURCE:  
CLONE: ZC13735  
US-09-081-180-29

Alignment\_scores:

Quality: 43.00 Length: 16  
Ratio: 3.583 Gaps: 0  
Percent Similarity: 75.000 Percent Identity: 50.000

Alignment\_block:  
US-09-439-311-2 x US-09-081-180-29 ..

Align seg 1/1 to: US-09-081-180-29 from: 1 to: 51

253 GlyValValIleGlyLysValAspTyrSerAspGlyAspGluAsnGly 268  
||||| :||| |||||:||||| |||:|||||  
1 GGTGAACCTTGCACAGAGATTACAGAGCAGTGTGACAGAGGT 48

seq\_name: /cgn2\_6/prodata/2/lna/6A\_COMB.seq:US-09-040-786-29

seq\_documentation\_block:  
Sequence 29, Application US/09040786  
Patent No. 6025197  
GENERAL INFORMATION:  
APPLICANT: Sheppard, Paul O.  
TITLE OF INVENTION: SECRETED SALIVARY ZSIG32  
TITLE OF INVENTION: POLYPEPTIDES  
NUMBER OF SEQUENCES: 38  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Zymogenetics  
STREET: 1201 Eastlake Ave. E.  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98102  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/040,786  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/041,263  
FILING DATE: March 19, 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Lingenfelter, Susan E  
REGISTRATION NUMBER: 41,156  
REFERENCE/DOCKET NUMBER: 97-17  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-442-6675  
TELEFAX: 206-442-6678  
TELEX:  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 51 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
IMMEDIATE SOURCE:  
CLONE: ZC13735  
US-09-040-786-29

Alignment\_scores:  
Quality: 43.00 Length: 16  
Ratio: 3.583 Gaps: 0  
Percent Similarity: 75.000 Percent Identity: 50.000

Alignment\_block:  
US-09-439-311-2 x US-09-040-786-29 ..

Align seg 1/1 to: US-09-040-786-29 from: 1 to: 51

```

NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 850-9900
TELEFAX: (303) 850-9401
INFORMATION FOR SEQ ID NO: 80:
SEQUENCE CHARACTERISTICS:
LENGTH: 60 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-219-012-80

alignment_scores:
Quality: 40.00 Length: 19
Ratio: 2.667 Gaps: 0
Percent Similarity: 78.947 Percent Identity: 42.105

alignment_block:
US-09-439-311-2 x US-08-219-012-80 ..

Align seg 1/1 to: US-08-219-012-80 from: 1 to: 60

204 ThrservalgIyThcIyLeuGlyAlaIalaenAlaIuclulIleasArGAs 2200
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
4 ACCGGGAGGAGGGCGTGGAGGCTGGAGCGCTGGCGCATGTGTAGGACGCGA 53

220 nAlaAsp 222
54 CTCGCAT 60

seq_name: /cgn2_6/plodata/2/lna/5B_COMB.seq:US-08-687-421-268
seq_documentation_block:
Sequence 268: Application US/08687421
Patent No. 6177557
GENERAL INFORMATION:
APPLICANT: Gold, Larry
APPLICANT: Janjic, Nebojsa
APPLICANT: Tasset, Diane
TITLE OF INVENTION: HIGH-AFFINITY LIGANDS OF BASIC
TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR AND
TITLE OF INVENTION: THROMBIN
NUMBER OF SEQUENCES: 445
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 Inch, 1.44 MB storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/687,421
FILING DATE: 08-MAY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/195,005
FILING DATE: 10-FEBRUARY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE: 22-APRIL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/219,012
FILING DATE: 28-MARCH-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/973,333

```



APPLICATION NUMBER: US 08/009,266  
FILING DATE: 22-JAN-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/894,061  
FILING DATE: 05-JUN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/889,724  
FILING DATE: 26-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/827,689  
FILING DATE: 27-JAN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Suh, Young J.  
REGISTRATION NUMBER: P-41,337  
REFERENCE/DOCKET NUMBER: 27866/32760  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: (312) 474-6600  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 47 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-483-389-97

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
US-09-439-311-2 x US-08-483-389-97/rev ..

Align seg 1/1 to reverse of: US-08-483-389-97 from: 1 to: 47

169 ArpneglutrhglySerclnSerPheSerSergly 180  
||||:||||||||| |||:|||||  
44 AGATGAGACTGGCTCAGCAGATTGGAGTGA 9

seq\_name: /cgn2\_6/pcodata/2/lna/5B\_COMB.seq:US-08-487-113D-97

seq\_documentation\_block:

; Sequence 97, Application US/08487113D  
; Patent No. 5837822  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 120  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/487,113D  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/286,754  
; FILING DATE: 05-AUG-1994  
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/102,852  
FILING DATE: 05-AUG-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/009,266  
FILING DATE: 22-JAN-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/894,061  
FILING DATE: 05-JUN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/889,724  
FILING DATE: 26-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/827,689  
FILING DATE: 27-JAN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 5837822and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 32744  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 47 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-487-113D-97

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
US-09-439-311-2 x US-08-487-113D-97/rev ..

Align seg 1/1 to reverse of: US-08-487-113D-97 from: 1 to: 47

169 ArpneglutrhglySerclnSerPheSerSergly 180  
||||:||||||||| |||:|||||  
44 AGATGAGACTGGCTCAGCAGATTGGAGTGA 9

seq\_name: /cgn2\_6/pcodata/2/lna/5B\_COMB.seq:US-08-473-503-97

seq\_documentation\_block:

; Sequence 97, Application US/08473503  
; Patent No. 5869262  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/473,503  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/286,754  
FILING DATE: 05-AUG-1994  
APPLICATION NUMBER: US 08/102,852  
FILING DATE: 05-AUG-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/009,266  
FILING DATE: 22-JAN-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/894,061  
FILING DATE: 05-JUN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/889,724  
FILING DATE: 26-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/827,689  
FILING DATE: 27-JAN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: NO. 5869262and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 32178  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 47 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-473-503-97

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

## alignment\_block:

US-09-439-311-2 x US-08-473-503-97/rev ..

Align seg 1/1 to reverse of: US-08-473-503-97 from: 1 to: 47

169 ArgpheglutrhglySerClnSerPheSerSergly 180

||||:||||||||||||| |||:|||||  
44 AGGATGAGACTGGCTCAGACAGATTGGAGTGA 9

seq\_name: /cgn2\_6/plodata/2/lna/5B\_COMB.seq:US-08-483-932-97

## seq\_documentation\_block:

; Sequence 97, Application US/08483932  
; Patent No. 5880268  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/483,932  
; FILING DATE: 07-JUN-1995

CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/286,754  
FILING DATE: 05-AUG-1994  
APPLICATION NUMBER: US 08/102,852  
FILING DATE: 05-AUG-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/009,266  
FILING DATE: 22-JAN-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/894,061  
FILING DATE: 05-JUN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/889,724  
FILING DATE: 26-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/827,689  
FILING DATE: 27-JAN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: NO. 5880268and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 32178  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 47 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-483-932-97

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

## alignment\_block:

US-09-439-311-2 x US-08-483-932-97/rev ..

Align seg 1/1 to reverse of: US-08-483-932-97 from: 1 to: 47

169 ArgpheglutrhglySerClnSerPheSerSergly 180

||||:||||||||||||| |||:|||||  
44 AGGATGAGACTGGCTCAGACAGATTGGAGTGA 9





OM of: US-09-439-311-2 to: GenEmbl.\* out\_format : pfs

Date: Apr 17, 2002 3:08 AM

About: Results were produced by the GenCore software, version 4.5,  
Copyright (c) 1993-2000 Compugen Ltd.

# Command line parameters:

-MODEL-frame+pn.model -DEV-rlp  
-Q/cgn2.1/USPTO.spool/US0943311/runat\_16042002\_134010\_11668/app-query.fasta\_1.395  
-DB-GenEmbl -OFMT-fastap -SUFFIX-rge -GAPOP-12.000 -GAPEXT-4.500  
-MINMATCH-0.100 -LOOPEL-0.000 -LOOPEXT-0.000 -OGAPOP-4.500  
-OGAPEXT-0.050 -XGAPOP-10.000 -XGAPEXT-0.500 -FGAPOP-6.000  
-FGAPEXT-7.000 -YGAPOP-10.000 -YGAPEXT-0.500 -DELOP-6.000  
-DELXT-7.000 -START-1 -MATRIX-biosum62 -TRANS-human40.ccd  
-LIST-45 -DOCALLIGN-200 -THR\_SCORE-pct -THR\_MAX-100 -THR\_MIN-0  
-ALIGN-15 -MODE-LOCAL -OUTFMT-pfs -NORM-ext -MINLEN-0 -MAXLEN-60  
-USER-US0943311\_cgn1\_1\_5662 -NCPU-6 -ICPU-3 -LONGLOG -NO\_XLPXY  
-MAIL -THREADS=1

## Search information block:

Query: US-09-439-311-2  
Query Length: 333  
Database: GenEmbl.\*  
Database sequences: 1472140  
Database length: -341344837  
Search time (sec): 1486.240000

seqname	Stcd	Orig	zScore	EScore	Len	Documentation
gb_pat:ARI53100	-	50.00	88.70	1.1e+04	30	ARI53100 Sequence 102 from patent
gb_pat:ARI53101	-	50.00	88.70	1.1e+04	30	ARI53101 Sequence 103 from patent
gb_pat:ARI53102	+	41.00	75.33	1.1e+04	30	ARI53102 Sequence 4 from Patent WO
gb_pat:ARI53103	+	41.00	75.17	6.4e+04	51	ARI53103 oligonucleotide, 12/1993
gb_pat:ARI53104	+	41.00	75.17	6.4e+04	51	ARI53104 oligonucleotide, 12/1993
gb_pat:ARI53105	+	41.00	75.17	6.4e+04	51	ARI53105 oligonucleotide, 12/1993
gb_pat:ARI53106	+	41.00	75.17	6.4e+04	51	ARI53106 oligonucleotide, 1/1994
gb_pat:ARI53107	+	40.00	72.89	8.5e+04	59	ARI53107 oligonucleotide, 1/1994
gb_pat:ARI53108	+	40.00	72.86	8.5e+04	60	ARI53108 Sequence 105 from patent
gb_pat:ARI53109	+	40.00	72.86	8.5e+04	60	ARI53109 Sequence 268 from patent
gb_pat:ARI53110	-	39.00	73.72	7.7e+04	47	ARI53110 Sequence 80 from patent
gb_pat:ARI53111	-	39.00	73.72	7.7e+04	47	ARI53111 Sequence 97 from patent
gb_pat:ARI53112	-	39.00	73.72	7.7e+04	47	ARI53112 Sequence 97 from patent
gb_pat:ARI53113	-	39.00	73.72	7.7e+04	47	ARI53113 Sequence 97 from patent
gb_pat:ARI53114	-	39.00	73.72	7.7e+04	47	ARI53114 Sequence 97 from patent
gb_pat:ARI53115	-	39.00	73.72	7.7e+04	47	ARI53115 Sequence 97 from patent
gb_pat:ARI53116	-	39.00	73.72	7.7e+04	47	ARI53116 Sequence 97 from patent
gb_pat:ARI53117	-	39.00	73.72	7.7e+04	47	ARI53117 Sequence 97 from patent
gb_pat:ARI53118	-	39.00	73.72	7.7e+04	47	ARI53118 Sequence 97 from patent
gb_pat:ARI53119	-	39.00	73.72	7.7e+04	47	ARI53119 Sequence 97 from patent
gb_pat:ARI53120	-	39.00	73.72	7.7e+04	47	ARI53120 Sequence 97 from patent
gb_pat:ARI53121	-	39.00	73.72	7.7e+04	47	ARI53121 Sequence 97 from patent
gb_pat:ARI53122	-	39.00	73.72	7.7e+04	47	ARI53122 Sequence 97 from patent
gb_pat:ARI53123	-	39.00	73.72	7.7e+04	47	ARI53123 Sequence 97 from patent
gb_pat:ARI53124	-	39.00	73.72	7.7e+04	47	ARI53124 Sequence 97 from patent
gb_pat:ARI53125	-	39.00	73.72	7.7e+04	47	ARI53125 Sequence 97 from patent
gb_pat:ARI53126	-	39.00	73.72	7.7e+04	47	ARI53126 Sequence 97 from patent
gb_pat:ARI53127	-	39.00	73.72	7.7e+04	47	ARI53127 Sequence 97 from patent
gb_pat:ARI53128	-	39.00	73.72	7.7e+04	47	ARI53128 Sequence 97 from patent
gb_pat:ARI53129	-	39.00	73.72	7.7e+04	47	ARI53129 Sequence 97 from patent
gb_pat:ARI53130	-	39.00	73.72	7.7e+04	47	ARI53130 Sequence 97 from patent
gb_pat:ARI53131	-	39.00	73.72	7.7e+04	47	ARI53131 Sequence 97 from patent
gb_pat:ARI53132	-	39.00	73.72	7.7e+04	47	ARI53132 Sequence 97 from patent
gb_pat:ARI53133	-	39.00	73.72	7.7e+04	47	ARI53133 Sequence 97 from patent
gb_pat:ARI53134	-	39.00	73.72	7.7e+04	47	ARI53134 Sequence 97 from patent
gb_pat:ARI53135	-	39.00	73.72	7.7e+04	47	ARI53135 Sequence 97 from patent
gb_pat:ARI53136	-	39.00	73.72	7.7e+04	47	ARI53136 Sequence 97 from patent
gb_pat:ARI53137	-	39.00	73.72	7.7e+04	47	ARI53137 Sequence 97 from patent
gb_pat:ARI53138	-	39.00	73.72	7.7e+04	47	ARI53138 Sequence 97 from patent
gb_pat:ARI53139	-	39.00	73.72	7.7e+04	47	ARI53139 Sequence 97 from patent
gb_pat:ARI53140	-	39.00	73.72	7.7e+04	47	ARI53140 Sequence 97 from patent
gb_pat:ARI53141	-	39.00	73.72	7.7e+04	47	ARI53141 Sequence 97 from patent
gb_pat:ARI53142	-	39.00	73.72	7.7e+04	47	ARI53142 Sequence 97 from patent
gb_pat:ARI53143	-	39.00	73.72	7.7e+04	47	ARI53143 Sequence 97 from patent
gb_pat:ARI53144	-	39.00	73.72	7.7e+04	47	ARI53144 Sequence 97 from patent
gb_pat:ARI53145	-	39.00	73.72	7.7e+04	47	ARI53145 Sequence 97 from patent
gb_pat:ARI53146	-	39.00	73.72	7.7e+04	47	ARI53146 Sequence 97 from patent
gb_pat:ARI53147	-	39.00	73.72	7.7e+04	47	ARI53147 Sequence 97 from patent
gb_pat:ARI53148	-	39.00	73.72	7.7e+04	47	ARI53148 Sequence 97 from patent
gb_pat:ARI53149	-	39.00	73.72	7.7e+04	47	ARI53149 Sequence 97 from patent
gb_pat:ARI53150	-	39.00	73.72	7.7e+04	47	ARI53150 Sequence 97 from patent
gb_pat:ARI53151	-	39.00	73.72	7.7e+04	47	ARI53151 Sequence 97 from patent
gb_pat:ARI53152	-	39.00	73.72	7.7e+04	47	ARI53152 Sequence 97 from patent
gb_pat:ARI53153	-	39.00	73.72	7.7e+04	47	ARI53153 Sequence 97 from patent
gb_pat:ARI53154	-	39.00	73.72	7.7e+04	47	ARI53154 Sequence 97 from patent
gb_pat:ARI53155	-	39.00	73.72	7.7e+04	47	ARI53155 Sequence 97 from patent
gb_pat:ARI53156	-	39.00	73.72	7.7e+04	47	ARI53156 Sequence 97 from patent
gb_pat:ARI53157	-	39.00	73.72	7.7e+04	47	ARI53157 Sequence 97 from patent
gb_pat:ARI53158	-	39.00	73.72	7.7e+04	47	ARI53158 Sequence 97 from patent
gb_pat:ARI53159	-	39.00	73.72	7.7e+04	47	ARI53159 Sequence 97 from patent
gb_pat:ARI53160	-	39.00	73.72	7.7e+04	47	ARI53160 Sequence 97 from patent
gb_pat:ARI53161	-	39.00	73.72	7.7e+04	47	ARI53161 Sequence 97 from patent
gb_pat:ARI53162	-	39.00	73.72	7.7e+04	47	ARI53162 Sequence 97 from patent
gb_pat:ARI53163	-	39.00	73.72	7.7e+04	47	ARI53163 Sequence 97 from patent
gb_pat:ARI53164	-	39.00	73.72	7.7e+04	47	ARI53164 Sequence 97 from patent
gb_pat:ARI53165	-	39.00	73.72	7.7e+04	47	ARI53165 Sequence 97 from patent
gb_pat:ARI53166	-	39.00	73.72	7.7e+04	47	ARI53166 Sequence 97 from patent
gb_pat:ARI53167	-	39.00	73.72	7.7e+04	47	ARI53167 Sequence 97 from patent
gb_pat:ARI53168	-	39.00	73.72	7.7e+04	47	ARI53168 Sequence 97 from patent
gb_pat:ARI53169	-	39.00	73.72	7.7e+04	47	ARI53169 Sequence 97 from patent
gb_pat:ARI53170	-	39.00	73.72	7.7e+04	47	ARI53170 Sequence 97 from patent
gb_pat:ARI53171	-	39.00	73.72	7.7e+04	47	ARI53171 Sequence 97 from patent
gb_pat:ARI53172	-	39.00	73.72	7.7e+04	47	ARI53172 Sequence 97 from patent
gb_pat:ARI53173	-	39.00	73.72	7.7e+04	47	ARI53173 Sequence 97 from patent
gb_pat:ARI53174	-	39.00	73.72	7.7e+04	47	ARI53174 Sequence 97 from patent
gb_pat:ARI53175	-	39.00	73.72	7.7e+04	47	ARI53175 Sequence 97 from patent
gb_pat:ARI53176	-	39.00	73.72	7.7e+04	47	ARI53176 Sequence 97 from patent
gb_pat:ARI53177	-	39.00	73.72	7.7e+04	47	ARI53177 Sequence 97 from patent
gb_pat:ARI53178	-	39.00	73.72	7.7e+04	47	ARI53178 Sequence 97 from patent
gb_pat:ARI53179	-	39.00	73.72	7.7e+04	47	ARI53179 Sequence 97 from patent
gb_pat:ARI53180	-	39.00	73.72	7.7e+04	47	ARI53180 Sequence 97 from patent
gb_pat:ARI53181	-	39.00	73.72	7.7e+04	47	ARI53181 Sequence 97 from patent
gb_pat:ARI53182	-	39.00	73.72	7.7e+04	47	ARI53182 Sequence 97 from patent
gb_pat:ARI53183	-	39.00	73.72	7.7e+04	47	ARI53183 Sequence 97 from patent
gb_pat:ARI53184	-	39.00	73.72	7.7e+04	47	ARI53184 Sequence 97 from patent
gb_pat:ARI53185	-	39.00	73.72	7.7e+04	47	ARI53185 Sequence 97 from patent
gb_pat:ARI53186	-	39.00	73.72	7.7e+04	47	ARI53186 Sequence 97 from patent
gb_pat:ARI53187	-	39.00	73.72	7.7e+04	47	ARI53187 Sequence 97 from patent
gb_pat:ARI53188	-	39.00	73.72	7.7e+04	47	ARI53188 Sequence 97 from patent
gb_pat:ARI53189	-	39.00	73.72	7.7e+04	47	ARI53189 Sequence 97 from patent
gb_pat:ARI53190	-	39.00	73.72	7.7e+04	47	ARI53190 Sequence 97 from patent
gb_pat:ARI53191	-	39.00	73.72	7.7e+04	47	ARI53191 Sequence 97 from patent
gb_pat:ARI53192	-	39.00	73.72	7.7e+04	47	ARI53192 Sequence 97 from patent
gb_pat:ARI53193	-	39.00	73.72	7.7e+04	47	ARI53193 Sequence 97 from patent
gb_pat:ARI53194	-	39.00	73.72	7.7e+04	47	ARI53194 Sequence 97 from patent
gb_pat:ARI53195	-	39.00	73.72	7.7e+04	47	ARI53195 Sequence 97 from patent
gb_pat:ARI53196	-	39.00	73.72	7.7e+04	47	ARI53196 Sequence 97 from patent
gb_pat:ARI53197	-	39.00	73.72	7.7e+04	47	ARI53197 Sequence 97 from patent
gb_pat:ARI53198	-	39.00	73.72	7.7e+04	47	ARI53198 Sequence 97 from patent
gb_pat:ARI53199	-	39.00	73.72	7.7e+04	47	ARI53199 Sequence 97 from patent
gb_pat:ARI53200	-	39.00	73.72	7.7e+04	47	ARI53200 Sequence 97 from patent
gb_pat:ARI53201	-	39.00	73.72	7.7e+04	47	ARI53201 Sequence 97 from patent
gb_pat:ARI53202	-	39.00	73.72	7.7e+04	47	ARI53202 Sequence 97 from patent
gb_pat:ARI53203	-	39.00	73.72	7.7e+04	47	ARI53203 Sequence 97 from patent
gb_pat:ARI53204	-	39.00	73.72	7.7e+04	47	ARI53204 Sequence 97 from patent
gb_pat:ARI53205	-	39.00	73.72	7.7e+04	47	ARI53205 Sequence 97 from patent
gb_pat:ARI53206	-	39.00	73.72	7.7e+04	47	ARI53206 Sequence 97 from patent
gb_pat:ARI53207	-	39.00	73.72	7.7e+04	47	ARI53207 Sequence 97 from patent
gb_pat:ARI53208	-	39.00	73.72	7.7e+04	47	ARI53208 Sequence 97 from patent
gb_pat:ARI53209	-	39.00	73.72	7.7e+04	47	ARI53209 Sequence 97 from patent
gb_pat:ARI53210	-	39.00	73.72	7.7e+04	47	ARI53210 Sequence 97 from patent
gb_pat:ARI53211	-	39.00	73.72	7.7e+04	47	ARI53211 Sequence 97 from patent
gb_pat:ARI53212	-	39.00	73.72	7.7e+04	47	ARI53212 Sequence 97 from patent
gb_pat:ARI53213	-	39.00	73.72	7.7e+04	47	ARI53213 Sequence 97 from patent
gb_pat:ARI53214	-	39.00	73.72	7.7e+04	47	ARI53214 Sequence 97 from patent
gb_pat:ARI53215	-	39.00	73.72	7.7e+04	47	ARI53215 Sequence 97 from patent
gb_pat:ARI53216	-	39.00	73.72	7.7e+04	47	ARI53216 Sequence 97 from patent
gb_pat:ARI53217	-	39.00	73.72	7.7e+04	47	ARI53217 Sequence 97 from patent
gb_pat:ARI53218	-	39.00	73.72	7.7e+04	47	ARI53218 Sequence 97 from patent
gb_pat:ARI53219	-	39.00	73.72	7.7e+04	47	ARI53219 Sequence 97 from patent
gb_pat:ARI53220	-	39.00	73.72	7.7e+04	47	ARI53220 Sequence 97 from patent
gb_pat:ARI53221	-	39.00	73.72	7.7e+04	47	ARI53221 Sequence 97 from patent
gb_pat:ARI53222	-	39.00	73.72	7.7e+04	47	ARI53222 Sequence 97 from patent
gb_pat:ARI53223	-	39.00	73.72	7.7e+04	47	ARI53223 Sequence 97 from patent
gb_pat:ARI53224	-	39.00	73.72	7.7e+04	47	ARI53224 Sequence 97 from patent
gb_pat:ARI53225	-	39.00	73.72	7.7e+04	47	ARI53225 Sequence 97 from patent
gb_pat:ARI53226	-	39.00	73.72	7.7e+04	47	ARI53226 Sequence 97 from patent
gb_pat:ARI53227	-	39.00	73.72	7.7e+04	47	ARI53227 Sequence 97 from patent
gb_pat:ARI53228	-	39.00	73.72	7.7e+04	47	ARI53228 Sequence 97 from patent
gb_pat:ARI53229	-	39.00	73.72	7.7e+04	47	ARI53229 Sequence 97 from patent
gb_pat:ARI53230	-	39.00	73.72	7.7e+04	47	ARI53230 Sequence 97 from patent
gb_pat:ARI53231	-	39.00	73.72	7.7e+04	47	ARI53231 Sequence 97 from patent
gb_pat:ARI53232	-	39.00	73.72	7.7e+04	47	ARI53232 Sequence 97 from patent
gb_pat:ARI53233	-	39.00	73.72	7.7e+04	47	ARI53233 Sequence 97 from patent
gb_pat:ARI53234	-	39.00	73.72	7.7e+04	47	ARI53234 Sequence 97 from patent
gb_pat:ARI53235	-	39.00	73.72	7.7e+04	47	ARI53235 Sequence 97 from patent
gb_pat:ARI53236	-	39.00	73.72	7.7e+04	47	ARI53236 Sequence 97 from patent
gb_pat:ARI53237	-	39.00	73.72	7.7e+04	47	ARI53237 Sequence 97 from patent
gb_pat:ARI53238	-	39.00	73.72	7.7e+04	47	ARI53238 Sequence 97 from patent
gb_pat:ARI53239	-	39.00	73.72	7.7e+04	47	ARI53239 Sequence 97 from patent
gb_pat:ARI53240	-	39.00	73.72	7.7e+04	47	ARI53240 Sequence 97 from patent
gb_pat:ARI53241	-	39.00	73.72	7.7e+04	47	ARI53241 Sequence 97 from patent
gb_pat:ARI53242	-	39.00	73.72	7.7e+04	47	ARI53242 Sequence 97 from patent
gb_pat:ARI53243	-	39.00	73.72	7.7e+04	47	ARI53243 Sequence 97 from patent
gb_pat:ARI53244	-	39.00	73.72	7.7e+04	47	ARI53244 Sequence 97 from patent
gb_pat:ARI53245	-	39.00	73.72	7.7e+04	47	ARI53245 Sequence 97 from patent
gb_pat:ARI53246	-	39.00	73.72	7.7e+04	47	ARI53246 Sequence 97 from patent
gb_pat:ARI53247	-	39.00	73.72	7.7e+04	47	ARI53247 Sequence 97 from patent
gb_pat:ARI53248	-	39.00	73.72	7.7e+04	47	ARI53248 Sequence 97 from patent
gb_pat:ARI53249	-	39.00	73.72	7.7e+04	47	ARI53249 Sequence 97 from patent
gb_pat:ARI53250	-	39.00	73.72	7.7e+04	47	ARI53250 Sequence 97 from patent
gb_pat:ARI53251	-	39.00	73.72	7.7e+04	47	ARI53251 Sequence 97 from patent
gb_pat:ARI53252	-	39.00	73.72	7.7e+04	47	ARI53252 Sequence 97 from patent
gb_pat:ARI53253	-	39.00	73.72	7.7e+04	47	ARI53253 Sequence 97 from patent
gb_pat:ARI53254	-	39.00	73.72	7.7e+04	47	ARI

US-09-439-311-2 x AR153101 ..

Align seg 1/1 to: AR153101 from: 1 to: 30

97 GlnAspGlyGlnSerLeuYsThrArgTyr 106  
|||||  
1 CAGATGCGACAGAGTTTAAACAGAGACT 30

seq\_name: gb\_pat:A93365

seq\_documentation\_block:

LOCUS A93365 50 bp DNA PAT 22-JAN-2000  
DEFINITION Sequence 4 from Patent WO9744451.  
ACCESSION A93365  
VERSION A93365.1 GI:6741628

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

BASE COUNT

ORIGIN

11 a 8 c 14 g 17 t

alignment\_scores:  
Quality: 41.00 Length: 10  
Ratio: 4.100 Gaps: 0  
Percent Similarity: 100.000 Percent Identity: 70.000

US-09-439-311-2 x A93365 ..

Align seg 1/1 to: A93365 from: 1 to: 50

262 SerAspGlyAspGlnAsnGlySerLeuIle 271  
|||||  
7 AGTGATGGTGAATGATGATGATCCTCTG 36

seq\_name: gb\_pat:A12323

seq\_documentation\_block:

LOCUS A12323 51 bp DNA PAT 06-DEC-1993  
DEFINITION oligonucleotide.  
ACCESSION A12323  
VERSION A12323.1 GI:491330

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

BASE COUNT

ORIGIN

alignment\_scores:  
Quality: 41.00 Length: 17  
Ratio: 3.154 Gaps: 0  
Percent Similarity: 76.471 Percent Identity: 47.059

alignment\_block:

US-09-439-311-2 x A12323/rev ..

Align seg 1/1 to reverse of: A12323 from: 1 to: 51

300 GlyArgGlyIleLysIleThrGlySerIleGlyValGlyAlaGlyIleLe 316  
|||  
51 GGGATCGGGGTTGGCGTTGGCGTTGGCGTTGGCGTTGGCGATCCT 2

316 u 316

1 c 1

seq\_name: gb\_pat:A12324

seq\_documentation\_block:

LOCUS A12324 51 bp DNA PAT 06-DEC-1993  
DEFINITION oligonucleotide.  
ACCESSION A12324  
VERSION A12324.1 GI:489519

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

BASE COUNT

ORIGIN

alignment\_scores:  
Quality: 41.00 Length: 17  
Ratio: 3.154 Gaps: 0  
Percent Similarity: 76.471 Percent Identity: 47.059

US-09-439-311-2 x A12324 ..

Align seg 1/1 to: A12324 from: 1 to: 51

300 GlyArgGlyIleLysIleThrGlySerIleGlyValGlyAlaGlyIleLe 316  
|||  
1 GGGATCGGGGTTGGCGTTGGCGTTGGCGTTGGCGTTGGCGATCCT 50

316 u 316

51 c 51

seq\_name: gb\_pat:A12596

seq\_documentation\_block:

LOCUS A12596 51 bp DNA PAT 05-JAN-1994  
DEFINITION oligonucleotide.  
ACCESSION A12596  
VERSION A12596.1 GI:491421

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

BASE COUNT

ORIGIN

alignment\_scores:  
Quality: 41.00 Length: 17  
Ratio: 3.154 Gaps: 0  
Percent Similarity: 76.471 Percent Identity: 47.059



seq\_name: gb\_pat:124293  
seq\_documentation\_block:  
LOCUS 124293 60 bp DNA PAT 07-OCT-1996  
DEFINITION Sequence 80 from patent US 5543293.  
ACCESSION 124293  
VERSION 124293.1 GI:1604163  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 60)  
AUTHORS Gold, L. and Tasset, D.  
TITLE DNA ligands of thrombin  
JOURNAL Patent: US 5543293-A 80 06-AUG-1996;  
FEATURES  
source 1..60  
location/Qualifiers  
BASE COUNT 10 a 11 c 29 g 10 t  
ORIGIN

alignment\_scores:  
Quality: 40.00 Length: 19  
Ratio: 2.67 Gaps: 0  
Percent Similarity: 78.947 Percent Identity: 42.105

alignment\_block:  
US-09-439-311-2 x 124293 ..  
Align seg 1/1 to: 124293 from: 1 to: 60

204 ThrSerValGlyThrGlyLeuGlyAlaLeuAlaGluGluLeuAsnArgAs 220  
||||: |||:||||| |||||||: :  
4 ACCGGCGAGCGCGTGGAGCGCTTGCGCATGTGTAGCGACGCA 53  
220 nAlaasp 222  
:::|  
54 CTCGGAT 60

seq\_name: gb\_pat:AR013897  
seq\_documentation\_block:  
LOCUS AR013897 47 bp DNA PAT 05-DEC-1998  
DEFINITION Sequence 97 from patent US 5773218.  
ACCESSION AR013897  
VERSION AR013897.1 GI:3971351  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 47)  
AUTHORS Gallatin, W. Michael and Vazeux, R.  
TITLE Method to identify compounds which modulate ICAM-related protein  
JOURNAL Patent: US 5773218-A 97 30-JUN-1998;  
FEATURES  
source 1..47  
location/Qualifiers  
BASE COUNT 9 a 21 c 7 g 10 t  
ORIGIN

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
US-09-439-311-2 x AR013897/rev ..  
Align seg 1/1 to reverse of: AR013897 from: 1 to: 47

169 ArgPheGluThrGlySerGlnSerPheSerSergly 180  
||||:|||||:|||||  
44 AGCATGGAGACTGGGTCAACACAGATTGTGGACTGCA 9

seq\_name: gb\_pat:AR033851  
seq\_documentation\_block:  
LOCUS AR033851 47 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 97 from patent US 5869262.  
ACCESSION AR033851  
VERSION AR033851.1 GI:5949456  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 47)  
AUTHORS Gallatin, W. Michael and Vazeux, R.  
TITLE Method for monitoring an inflammatory disease state by detecting  
JOURNAL Patent: US 5869262-A 97 09-FEB-1999;  
FEATURES  
source 1..47  
location/Qualifiers  
BASE COUNT 9 a 21 c 7 g 10 t  
ORIGIN

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
US-09-439-311-2 x AR033851/rev ..  
Align seg 1/1 to reverse of: AR033851 from: 1 to: 47

169 ArgPheGluThrGlySerGlnSerPheSerSergly 180  
||||:|||||:|||||  
44 AGCATGGAGACTGGGTCAACACAGATTGTGGACTGCA 9

seq\_name: gb\_pat:AR042511  
seq\_documentation\_block:  
LOCUS AR042511 47 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 97 from patent US 5811517.  
ACCESSION AR042511  
VERSION AR042511.1 GI:5963007  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 47)  
AUTHORS Gallatin, W. Michael and Vazeux, R.  
TITLE ICAM-related protein variants  
JOURNAL Patent: US 5811517-A 97 22-SEP-1998;  
FEATURES  
source 1..47  
location/Qualifiers  
BASE COUNT 9 a 21 c 7 g 10 t  
ORIGIN

alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
US-09-439-311-2 x AR042511/rev ..  
Align seg 1/1 to reverse of: AR042511 from: 1 to: 47

169 ArpPhegluThrGlySerGlnSerPheSerSergly 180  
 |||:::|||||  
 44 AGGATGGAGACTGGGTCAACACGATTTGGGAGTGA 9

seq\_name: gb\_pat:AR058391

seq\_documentation\_block:

LOCUS AR058391 47 bp DNA PAT 29-SEP-1999  
 DEFINITION Sequence 97 from patent US 5837822.  
 ACCESSION AR058391  
 VERSION AR058391.1 GI:5983968  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 UNCLASSIFIED.

REFERENCE 1 (bases 1 to 47)  
 AUTHORS Gallatin,W.Michael and Vazeux,R.  
 TITLE Humanized antibodies specific for ICAM related protein  
 JOURNAL Patent: US 5837822-A 97 17-NOV-1998;  
 FEATURES Location/Qualifiers  
 source 1..47  
 /organism="unknown"

BASE COUNT 9 a 21 c 7 g 10 t  
 ORIGIN

alignment\_scores:

Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:

US-09-439-311-2 x AR058391/rev ..

Align seg 1/1 to reverse of: AR058391 from: 1 to: 47

169 ArpPhegluThrGlySerGlnSerPheSerSergly 180  
 |||:::|||||  
 44 AGGATGGAGACTGGGTCAACACGATTTGGGAGTGA 9

seq\_name: gb\_pat:AR08217

seq\_documentation\_block:

LOCUS AR08217 47 bp DNA PAT 07-SEP-2000  
 DEFINITION Sequence 97 from patent US 5989843.  
 ACCESSION AR08217  
 VERSION AR08217.1 GI:10014980  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 UNCLASSIFIED.

REFERENCE 1 (bases 1 to 47)  
 AUTHORS Gallatin,W.Michael and Vazeux,R.  
 TITLE Methods for identifying modulators of protein kinase C  
 JOURNAL Patent: US 5989843-A 97 23-NOV-1999;  
 FEATURES Location/Qualifiers  
 source 1..47  
 /organism="unknown"

BASE COUNT 9 a 21 c 7 g 10 t  
 ORIGIN

alignment\_scores:

Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:

US-09-439-311-2 x AR08217/rev ..

Align seg 1/1 to reverse of: AR08217 from: 1 to: 47

169 ArpPhegluThrGlySerGlnSerPheSerSergly 180  
 |||:::|||||  
 44 AGGATGGAGACTGGGTCAACACGATTTGGGAGTGA 9

Wed Apr 17 07:36:47 2002

us-09-439-311-2.rge

---

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 16, 2002, 23:26:24 ; Search time 1531.8 Seconds  
(without alignments)

10759.030 Million cell updates/sec

Title: US-09-439-311-1

Perfect score: 999  
Sequence: 1 attacacaatgttcagc.....ttaaaatgatgtatagat 999

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 1472140 seqs, 8248589755 residues

Total number of hits satisfying chosen parameters: 586436

Minimum DB seq length: 0  
Maximum DB seq length: 60

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

GenBml: \*  
1: gb\_ba: \*  
2: gb\_hlg: \*  
3: gb\_in: \*  
4: gb\_com: \*  
5: gb\_ov: \*  
6: gb\_pat: \*  
7: gb\_ph: \*  
8: gb\_pl: \*  
9: gb\_pr: \*  
10: gb\_ro: \*  
11: gb\_sts: \*  
12: gb\_sy: \*  
13: gb\_un: \*  
14: gb\_vl: \*  
15: em\_ba: \*  
16: em\_fun: \*  
17: em\_hum: \*  
18: em\_in: \*  
19: em\_om: \*  
20: em\_or: \*  
21: em\_ov: \*  
22: em\_pat: \*  
23: em\_ph: \*  
24: em\_pl: \*  
25: em\_ro: \*  
26: em\_sts: \*  
27: em\_sy: \*  
28: em\_un: \*  
29: em\_vl: \*  
30: em\_hlg\_hum: \*  
31: em\_hlg\_inv: \*  
32: em\_hlg\_rod: \*  
33: em\_hlg\_hum: \*  
34: em\_hlg\_inv: \*  
35: em\_hlg\_rod: \*  
36: em\_hlg\_other: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	26.8	2.7	30	6	ARI53100	ARI53100 Sequence
2	26.8	2.7	30	6	ARI53101	ARI53101 Sequence
3	21.4	2.1	60	3	AF320167	AF320167 Drosophila
C 4	20.8	2.1	24	6	AR001228	AR001228 Sequence
C 5	20.8	2.1	24	6	AR008251	AR008251 Sequence
C 6	20.8	2.1	24	6	AR010178	AR010178 Sequence
C 7	20.8	2.1	24	6	AR054102	AR054102 Sequence
C 8	20.8	2.1	24	6	I38291	I38291 Sequence 6
C 9	20.8	2.1	44	6	AX052949	AX052949 Sequence
C 10	20.8	2.1	58	6	AR061278	AR061278 Sequence
11	20.6	2.1	60	6	AR04005	AR04005 Sequence 17
12	20.4	2.0	51	6	AX160493	AX160493 Sequence
13	20.4	2.0	51	6	AX160494	AX160494 Sequence
14	20.4	2.0	57	3	AF320169	AF320169 Drosophila
15	20.4	2.0	57	3	AF320170	AF320170 Drosophila
16	20.4	2.0	57	3	AF320171	AF320171 Drosophila
17	20.4	2.0	57	3	AF320172	AF320172 Drosophila
18	20.4	2.0	57	3	AF320173	AF320173 Drosophila
19	20.4	2.0	57	3	AF320174	AF320174 Drosophila
20	20.4	2.0	57	3	AF320175	AF320175 Drosophila
21	20.4	2.0	57	3	AF320176	AF320176 Drosophila
22	20.4	2.0	57	3	AF320177	AF320177 Drosophila
23	20.4	2.0	57	3	AF320178	AF320178 Drosophila
24	20.4	2.0	57	3	AF320179	AF320179 Drosophila
25	20.2	2.0	52	6	A69988	A69988 Sequence 19
C 26	20	2.0	50	6	A17107	A17107 Oligonucleo
C 27	20	2.0	50	6	AR027492	AR027492 Sequence
C 28	20	2.0	57	6	AR077133	AR077133 Sequence
29	20	2.0	57	6	AR102800	AR102800 Sequence
30	20	2.0	57	6	I21136	I21136 Sequence 4
31	20	2.0	60	6	A38623	A38623 Sequence 16
32	20	2.0	60	6	AR040717	AR040717 Sequence
C 33	19.8	2.0	51	6	AX165291	AX165291 Sequence
C 34	19.8	2.0	59	6	AX011435	AX011435 Sequence
C 35	19.6	2.0	29	6	A20557	A20557 Oligonucleo
C 36	19.6	2.0	43	6	I11627	I11627 Sequence 12
C 37	19.6	2.0	51	6	AX160235	AX160235 Sequence
38	19.6	2.0	55	14	HIY1045041	U45041 Human Immun
39	19.6	2.0	57	6	A32988	A32988 Synthetic P
C 40	19.6	2.0	58	6	AR011305	AR011305 Sequence
C 41	19.6	2.0	58	6	I17943	I17943 Sequence 17
C 42	19.4	1.9	37	6	AR063204	AR063204 Sequence
C 43	19.4	1.9	49	14	ALAM03	V00054 Alfalfa mos
44	19.4	1.9	51	6	AX117493	AX117493 Sequence
C 45	19.4	1.9	51	6	AX162140	AX162140 Sequence

## ALIGNMENTS

RESULT	LOCUS	SEQUENCE	bp	DNA	PAT	08-AUG-2001
1	ARI53100/c	Sequence 102 from patent US 6235480.				
ACCESSION	ARI53100					
VERSION	ARI53100.1	GI:15120632				
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 30)					
AUTHORS	Shultz, J. William, Lewis, M. K., Leippe, D., Mandrek, M., Kephart, D., Rhodes, R. Byron, Andrews, C. Ann, Hartnett, J. Robert, Gu, T., Olson, R. J., Wood, K. V. and Welch, R.					
TITLE	Detection of nucleic acid hybrids					
JOURNAL	Patent: US 6235480-A 102 22-MAY-2001;					
FEATURES	Location/Qualifiers					
SOURCE	1..30					
BASE COUNT	5 a 5 c 4 g 16 t					





JOURNAL Patent: US 5753444-A 6 19-MAY-1998;

FEATURES Location/Qualifiers  
Source 1..24  
/organism="unknown"

BASE COUNT 6 a 5 c 5 g 8 t

ORIGIN

Query Match 2.1%; Score 20.8; DB 6; Length 24;

Best Local Similarity 91.7%; Pred. No. 1.9e+06; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 2;

QY 91 ggcctagaatcaactccgcagca 114

Db 24 GGCTTAGAATTAACTCAGCAGCA 1

RESULT 6

LOCUS AR010178 24 bp DNA

DEFINITION Sequence 6 from patent US 5756701.

ACCESSION AR010178

VERSION AR010178.1 GI:3968983

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 24)

AUTHORS Wu, L., Coombs, J., Malmstrom, S.L. and Glass, M.J.

TITLE Specific oligonucleotide primer pairs and probes for discriminating

JOURNAL Patent: US 5756701-A 6 26-MAY-1998;

FEATURES Location/Qualifiers

source 1..24

BASE COUNT 6 a 5 c 5 g 8 t

ORIGIN

Query Match 2.1%; Score 20.8; DB 6; Length 24;

Best Local Similarity 91.7%; Pred. No. 1.9e+06; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 2;

QY 91 ggcctagaatcaactccgcagca 114

Db 24 GGCTTAGAATTAACTCAGCAGCA 1

RESULT 7

LOCUS AR064102 24 bp DNA

DEFINITION Sequence 6 from patent US 5846783.

ACCESSION AR064102

VERSION AR064102.1 GI:5993410

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 24)

AUTHORS Wu, L., Coombs, J., Malmstrom, S.L. and Glass, M.J.

TITLE Methods and apparatus for preparing, amplifying, and discriminating

JOURNAL Patent: US 5846783-A 6 08-DEC-1998;

FEATURES Location/Qualifiers

source 1..24

BASE COUNT 6 a 5 c 5 g 8 t

ORIGIN

Query Match 2.1%; Score 20.8; DB 6; Length 24;

Best Local Similarity 91.7%; Pred. No. 1.9e+06; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 2;

QY 91 ggcctagaatcaactccgcagca 114

Db 24 GGCTTAGAATTAACTCAGCAGCA 1

RESULT 8

LOCUS I38291 24 bp DNA

DEFINITION Sequence 6 from patent US 5612473.

ACCESSION I38291

VERSION I38291.1 GI:2086281

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 24)

AUTHORS Wu, L., Coombs, J., Malmstrom, S.L. and Glass, M.J.

TITLE Methods, kits and solutions for preparing sample material for

JOURNAL Patent: US 5612473-A 6 18-MAR-1997;

FEATURES Location/Qualifiers

source 1..24

BASE COUNT 6 a 5 c 5 g 8 t

ORIGIN

Query Match 2.1%; Score 20.8; DB 6; Length 24;

Best Local Similarity 91.7%; Pred. No. 1.9e+06; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 2;

QY 91 ggcctagaatcaactccgcagca 114

Db 24 GGCTTAGAATTAACTCAGCAGCA 1

RESULT 9

LOCUS AX052949 44 bp DNA

DEFINITION Sequence 55 from Patent WO0071755.

ACCESSION AX052949

VERSION AX052949.1 GI:12227051

KEYWORDS

SOURCE Synthetic construct.

ORGANISM Synthetic construct.

REFERENCE 1 (bases 1 to 44)

AUTHORS Kwach, J.G., Macklin, J.J., Mitsis, P.G. and Uimer, K.M.

TITLE Method for sequencing and characterizing polymeric biomolecules using

JOURNAL aptamers and a method for producing aptamers

Patent: WO 0071755-A 55 30-NOV-2000;

FEATURES Incorporated (US)

Location/Qualifiers

source 1..44

BASE COUNT 9 a 6 c 19 g 10 t

ORIGIN

Query Match 2.1%; Score 20.8; DB 6; Length 44;

Best Local Similarity 70.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;

Matches 28; Conservative 0; Mismatches 12;

QY 747 tgcatacatgggggttgtaggtgaagtgcattca 786

Db 4 TGACACCACTGGGGGTGATGGGTAGCGTTTGGAATCA 43

RESULT 10

LOCUS AR061278/c

LOCUS AR061278 58 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 7 from patent US 5843650.  
ACCESSION AR061278  
VERSION AR061278.1 GI:5988969  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 58)  
AUTHORS Segev,D.  
TITLE Nucleic acid detection and amplification by chemical linkage of  
JOURNAL oligonucleotides  
FEATURES Patent: US 5843650-A 7 01-DEC-1998;  
source Location/Qualifiers  
1..58  
BASE COUNT 15 a 18 c 13 g 12 t  
ORIGIN

Query Match 2.1%; Score 20.8; DB 6; Length 58;  
Best Local Similarity 60.7%; Pred. No. 1.8e+06;  
Matches 34; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Oy 789 tggatgagaaatggtcttaattcagctatcaatgctgtaaaagatacaactg 844  
Db 58 TGATGCTGAGAGATGGCCTCGGTCATGCTGCCATGACGAGACGTGTACACATG 3

RESULT 11  
LOCUS AB0405 60 bp DNA PAT 21-JAN-2000  
DEFINITION Sequence 17 from Patent WO951771.  
ACCESSION AB0405  
VERSION AB0405.1 GI:6731293  
KEYWORDS Archaeoglobus fulgidus.  
SOURCE Archaeoglobus fulgidus.  
ORGANISM Archaeoglobus fulgidus.  
REFERENCE 1 (bases 1 to 60)  
AUTHORS Jensen,R. and Schouls,L.M.  
TITLE A METHOD OF INTERSTRAIN DIFFERENTIATION OF BACTERIA  
JOURNAL Patent: WO 951771-A 17 14-OCT-1999; JANSSEN RUDOLPH (NL)  
FEATURES EMBDEN JOHANNES DIRK ANTHONIE (NL); JANSSEN RUDOLPH (NL)  
source Location/Qualifiers  
1..60  
misc\_feature /organism="Archaeoglobus fulgidus"  
/db\_xref="taxon:2234"  
BASE COUNT 20 a 11 c 9 g 20 t  
ORIGIN

Query Match 2.1%; Score 20.6; DB 6; Length 60;  
Best Local Similarity 62.7%; Pred. No. 2e+06;  
Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Oy 561 aaactacacggtatcgaagatttaattgatagtgtagttcttac 611  
Db 10 AGACCAAAAGGAGTGAATCTTCAATCCCATTTTGGCTGATTTCAC 60

RESULT 12  
LOCUS AX160493 51 bp DNA PAT 22-JUN-2001  
DEFINITION Sequence 3821 from Patent WO0140521.  
ACCESSION AX160493  
VERSION AX160493.1 GI:14541824  
KEYWORDS human.  
SOURCE Homo sapiens  
ORGANISM Homo sapiens; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 51)  
AUTHORS Shimkets,R.A. and Leach,M.  
TITLE Nucleic acids containing single nucleotide polymorphisms and  
JOURNAL methods of use thereof  
FEATURES Patent: WO 0140521-A 3821 07-JUN-2001;  
source Curagen Corporation (US)  
1..51  
Location/Qualifiers  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"

misc\_feature

/note="1 of 2 allelic variants (3822 is other entry)"  
Accession number cg43921050"

BASE COUNT 19 a 5 c 8 g 19 t  
ORIGIN

Query Match 2.0%; Score 20.4; DB 6; Length 51;  
Best Local Similarity 65.2%; Pred. No. 2.2e+06;  
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Oy 858 taaagatgaaatgtaactgttcttacttcggccgagtaga 903  
Db 4 TAAAGATGAACAGTAAAGCCATTTTGTGGAAGATGTAGA 49

RESULT 13  
LOCUS AX160494 51 bp DNA PAT 22-JUN-2001  
DEFINITION Sequence 3822 from Patent WO0140521.  
ACCESSION AX160494  
VERSION AX160494.1 GI:14541825  
KEYWORDS human.  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 51)  
AUTHORS Shimkets,R.A. and Leach,M.  
TITLE Nucleic acids containing single nucleotide polymorphisms and  
JOURNAL methods of use thereof  
FEATURES Patent: WO 0140521-A 3822 07-JUN-2001;  
source Curagen Corporation (US)  
1..51  
Location/Qualifiers  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
misc\_feature /note="2 of 2 allelic variants (3821 is other entry)"  
Accession number cg43921050"  
BASE COUNT 18 a 5 c 8 g 20 t  
ORIGIN

Query Match 2.0%; Score 20.4; DB 6; Length 51;  
Best Local Similarity 65.2%; Pred. No. 2.2e+06;  
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Oy 858 taaagatgaaatgtaactgttcttacttcggccgagtaga 903  
Db 4 TAAAGATGAACAGTAAAGCCATTTTGTGGAAGATGTAGA 49

RESULT 14  
LOCUS AF320169 57 bp DNA INV 23-APR-2001  
DEFINITION Drosophila pseudoobscura strain Mather10 bicoid (bcd) gene, partial  
ACCESSION AF320169  
VERSION AF320169.1 GI:13752326  
KEYWORDS cds.  
SOURCE Drosophila pseudoobscura.  
ORGANISM Drosophila pseudoobscura

[illegible]

```

FEATURES
SOURCE
location/Qualifiers
1..57
/organism="Drosophila pseudoobscura"
/strain="Mather17"
/db_xref="taxon:7237"
<1..>57
/gene="bcd"
<1..>57
/gene="bcd"
/number=3
repeat_region
1..57
/note="microsatellite"
/rpt_type=tandem
<1..>57
/gene="bcd"
/codon_start=1
/product="bicoid"
/protein_id="AAK38622.1"
/db_xref="GI:13752329"
/translation="AQFQOTQ0000LHQ00000"
BASE COUNT
19 a 19 c 12 g 7 t
ORIGIN
Query Match 2.0%; Score 20.4; DB 3; Length 57;
Best Local Similarity 61.1%; Pred. No. 2.2e+06;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0.
QY 89 caggtccttagaatcaactccgcagcagcagatgatgctctcaggcgatgcatagcag 142
||| ||||| | | | ||||| | | | |||
Db 4 CAGTTCCTTTCAGACACACAGCAGCAGCAGCTCCATCAGCAGCAGCAGCAG 57

```



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 17, 2002, 01:18:44 ; Search time 172.86 Seconds  
(without alignments)  
4954.691 Million cell updates/sec

Title: US-09-439-311-1

Perfect score: 999  
Sequence: 1 attacacaatgttcgacg.....ttaaaatgatgttagatg 999

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 930621 seqs, 428662619 residues

Total number of hits satisfying chosen parameters: 1026190

Minimum DB seq length: 0  
Maximum DB seq length: 60

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N.Geneseq\_1101:\*

- 1: /SID2/gcgdata/geneseq/geneseq/NA1980.DAT:\*
- 2: /SID2/gcgdata/geneseq/geneseq/NA1981.DAT:\*
- 3: /SID2/gcgdata/geneseq/geneseq/NA1982.DAT:\*
- 4: /SID2/gcgdata/geneseq/geneseq/NA1983.DAT:\*
- 5: /SID2/gcgdata/geneseq/geneseq/NA1984.DAT:\*
- 6: /SID2/gcgdata/geneseq/geneseq/NA1985.DAT:\*
- 7: /SID2/gcgdata/geneseq/geneseq/NA1986.DAT:\*
- 8: /SID2/gcgdata/geneseq/geneseq/NA1987.DAT:\*
- 9: /SID2/gcgdata/geneseq/geneseq/NA1988.DAT:\*
- 10: /SID2/gcgdata/geneseq/geneseq/NA1989.DAT:\*
- 11: /SID2/gcgdata/geneseq/geneseq/NA1990.DAT:\*
- 12: /SID2/gcgdata/geneseq/geneseq/NA1991.DAT:\*
- 13: /SID2/gcgdata/geneseq/geneseq/NA1992.DAT:\*
- 14: /SID2/gcgdata/geneseq/geneseq/NA1993.DAT:\*
- 15: /SID2/gcgdata/geneseq/geneseq/NA1994.DAT:\*
- 16: /SID2/gcgdata/geneseq/geneseq/NA1995.DAT:\*
- 17: /SID2/gcgdata/geneseq/geneseq/NA1996.DAT:\*
- 18: /SID2/gcgdata/geneseq/geneseq/NA1997.DAT:\*
- 19: /SID2/gcgdata/geneseq/geneseq/NA1998.DAT:\*
- 20: /SID2/gcgdata/geneseq/geneseq/NA1999.DAT:\*
- 21: /SID2/gcgdata/geneseq/geneseq/NA2000.DAT:\*
- 22: /SID2/gcgdata/geneseq/geneseq/NA2001.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	26.8	2.7	30	21	AAA86891
2	26.8	2.7	30	21	AAA86892
3	26.8	2.7	30	21	AAA93188
4	26.8	2.7	30	21	AAA93190
5	21.4	2.2	50	20	AAV52169
6	21.4	2.2	51	19	AAV04223
7	21.4	2.1	58	19	AAV04224
8	21.2	2.1	54	21	AAV97417
9	21	2.1	37	21	AAA27148
10	21	2.1	33	21	AAA27149
11	20.8	2.1	24	18	AA760508

C 12	20.8	2.1	24	19	AAV31446	Campylobacter nucl
C 13	20.8	2.1	24	19	AAV25942	Oligonucleotide PC
C 14	20.8	2.1	24	19	AAV20847	Campylobacter CF04
C 15	20.8	2.1	44	22	AA716711	dGMP-specific apta
C 16	20.8	2.1	50	18	AAV76100	Staphylococcus aur
C 17	20.8	2.1	51	22	AAH89291	Human coding sequ
C 18	20.8	2.1	58	19	AAV15200	Human serrate 2 PC
C 19	20.6	2.1	47	21	AAZ67004	Human map-related
C 20	20.6	2.1	51	18	AA770191	Human map-related
C 21	20.6	2.1	51	20	AAV16831	Primer SEQ ID NO:2
C 22	20.4	2.0	47	21	AAZ66354	Human delta-1 gene
C 23	20.4	2.0	47	21	AAZ68687	Human map-related
C 24	20.4	2.0	50	16	AAZ25074	Human gene signatu
C 25	20.2	2.0	50	22	AAH25533	PCR primer used to
C 26	20.2	2.0	50	22	AAH25535	PCR primer used to
C 27	20.2	2.0	59	21	AAZ24094	Human secreted pro
C 28	20.2	2.0	60	16	AAV21562	Human gene signatu
C 29	20	2.0	39	19	AAV05387	Primer PAS3BACREV
C 30	20	2.0	39	21	AAV55959	Sequencing and PCR
C 31	20	2.0	44	21	AAZ55398	Neisseria species
C 32	20	2.0	52	20	AAV16314	Human delta-2 prim
C 33	20	2.0	57	20	AAZ07541	ST receptor peptid
C 34	20	2.0	60	15	AAQ66366	McPC603 V-min gene
C 35	20	2.0	60	17	AAV38741	Moraxella outer me
C 36	19.8	2.0	45	22	AAV30242	Dystrophin exon 3
C 37	19.8	2.0	47	21	AAZ69525	Human map-related
C 38	19.8	2.0	59	21	AAZ96831	S. cerevisiae gene
C 39	19.6	2.0	36	14	AAQ40036	Sequence of revers
C 40	19.6	2.0	43	16	AAQ89640	Reverse primer 99R
C 41	19.6	2.0	47	21	AAZ66795	Human map-related
C 42	19.6	2.0	47	21	AAZ67933	Human map-related
C 43	19.6	2.0	57	13	AAQ23824	Primer HnclambdaFO
C 44	19.6	2.0	58	13	AAQ35636	SIV env primer SIV
C 45	19.6	2.0	58	14	AAQ35359	PCR primer STEVEN4

## ALIGNMENTS

RESULT 1	
AAA86891/c	
ID	AAA86891 standard; DNA: 30 BP.
AC	AAA86891:
XX	
DT	15-JAN-2001 (first entry)
XX	
DE	Probe to Campylobacter jejuni.
XX	
KW	Detection: nucleic acid hybrid; depolymerisation: analysis: SNP;
KW	single nucleotide polymorphism; identification: viral load; probe;
KW	genotyping; medical marker diagnostic; primer: target; mutation;
KW	genetic disease: ss.
XX	
OS	Campylobacter jejuni.
XX	
PN	MO200049180-A1.
PD	
XX	
PF	24-AUG-2000.
XX	
PR	18-FEB-2000: 2000WO-US04242.
XX	
PR	18-FEB-1999: 99US-0252436.
XX	
PR	21-JUL-1999: 99US-0358972.
XX	
PR	25-AUG-1999: 99US-0383316.
XX	
PA	(PROM-) PROMEGA CORP.
XX	
PI	Shultz JM, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;
XX	Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;
XX	WPI; 2000-565377/52.

```

PT acid sequence by using an enzyme that depolymerizes the 3' end of an
PT oligonucleotide probe hybridized to a target sequence to release
PT identifier nucleotides
XX
XX
PS Example: Page 321: 389pp; English.
XX
CC The present invention describes a method (M1) for determining the
CC presence or absence of a predetermined endogenous nucleic acid target
CC sequence (ENMT). The method comprises hybridizing a probe having an
CC identifier nucleotide (IN) with ENMT which is treated with an enzyme
CC that depolymerizes the 3' end of hybridised NA to release the INs.
CC M1 is used for determining the number of known sequence repeats present
CC in a nucleic acid target sequence in a nucleic acid sample. The method
CC is also useful for determining whether a nucleic acid target sequence in
CC a sample is an allele from a homozygous or heterozygous locus. The
CC method is also useful for detection of mutations, translocations and
CC SNPs in nucleic acids (including those associated with genetic disease),
CC determination of viral load, species identification, sample
CC contamination, and analysis of forensic samples. AAB6701 to AAB8709
CC and AAB12017 represent sequence which are used in the exemplification of
CC the present invention.
CC N.B. There is a discrepancy between the SEQ ID NO: and sequences given
CC in the examples, and the SEQ ID NO: and sequences given in the sequence
CC listing from the present invention.
XX
SQ Sequence 30 BP, 16 A; 4 C; 5 G; 5 T; 0 other;
XX
Query Match 2.7%; Score 26.8; DB 21; Length 30;
Best Local Similarity 93.3%; Pred. No. 1.3e+03;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 289 caagatggtcaagcttaaaacaagaact 318
DB 1 caagatggtcaagcttaaaacaagaact 30
|||||
RESULT 3
ID AAA93188/c
ID AAA93188 standard; DNA; 30 BP.
XX
XX AAA93188;
XX
XX 11-JAN-2001 (first entry)
XX
XX Campylobacter jejuni interrogation probe 11451.
XX
XX Campylobacter jejuni; nucleic acid detection; genomic typing;
XX mutation detection; viral load determination; species identification;
XX forensic analysis; probe; ss.
XX
XX OS Campylobacter jejuni.
XX
XX PN WO200049179-A1.
XX
XX PD 24-AUG-2000.
XX
XX PE 18-FEB-2000; 2000WO-US04176.
XX
XX PR 18-FEB-1999; 99US-0252436.
XX PR 21-JUL-1999; 99US-0358972.
XX PR 27-SEP-1999; 99US-0406147.
XX
XX PA (PROM-) PROMEGA CORP.
XX
XX Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;
XX Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;
XX WPI, 2000-549282/50.
XX
XX Detecting the presence of predetermined exogenous nucleic acid target
XX sequence useful for e.g. genotyping, comprises depolymerizing the 3'
XX end of an oligonucleotide probe hybridized to a nucleic acid target

```

PT sequence -  
XX  
PS Claim 47; Page 187; 230pp; English.  
XX  
CC The present sequence is an interrogation probe which was used to detect a  
CC segment of the genome of *Campylobacter jejuni*. This was performed as part  
CC of a method for determining the presence of a known exogenous nucleic  
CC acid target sequence in a nucleic acid sample. The method comprises  
CC admixing a treated sample with a depolymerizing enzyme which releases one  
CC or more nucleotides from the 3'-end of a hybridised nucleic acid probe.  
CC The method is used for assaying nucleic acids for a particular native or  
CC mutant sequence, and for genomic typing. It is useful for detecting  
CC mutations, translocations, and single nucleotide polymorphisms,  
CC determination of viral load, species identification, detection of sample  
CC contamination, and analysis of forensic samples. Compared with previous  
CC methods of detecting nucleic acid hybrids, the new method has higher  
CC sensitivity without the need for radiochemicals or electrophoresis. It is  
CC quantitative, highly reproducible and can be automated. The method can  
CC reliably detect as few as 10 copies of a virus in a sample, and is  
CC capable of providing multiple analyses in a single assay (multiplex  
CC assay).  
XX  
SQ Sequence 30 BP; 5 A; 5 C; 4 G; 16 T; 0 other;  
XX  
Query Match 2.7%; Score 26.8; DB 21; Length 30;  
Best Local Similarity 93.3%; Pred. No. 1.3e+03;  
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 289 caagatggtcaaacgttaaaacagaact 318  
Db 30 CAAGATGCAACAAAGTTTAAAAACAAGACT 1  
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  
RESULT 4  
AA93190  
ID AAA93190 standard; DNA: 30 BP.  
XX  
AC AAA93190;  
XX  
XX 11-JAN-2001 (first entry)  
XX  
DE *Campylobacter jejuni* Interrogation probe 11450.  
XX  
KM *Campylobacter jejuni*; nucleic acid detection; genomic typing;  
KM mutation detection; viral load determination; species identification;  
KM forensic analysis; probe: ss.  
XX  
OS *Campylobacter jejuni*.  
XX  
PN WO200049179-A1.  
XX  
PD 24-AUG-2000.  
XX  
PF 18-FEB-2000; 2000WO-US04176.  
XX  
PR 18-FEB-1999; 99US-0252436.  
PR 21-JUL-1999; 99US-0358972.  
PR 27-SEP-1999; 99US-0406147.  
XX  
PA (PROM-) PROMEGA CORP.  
XX  
PI Shultz JM, Lewis MK, Lelape D, Mandrekar M, Kephart D, Rhodes RB;  
PI Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;  
XX  
DR WPI; 2000-549282/50.  
XX  
PT Detecting the presence of predetermined exogenous nucleic acid target  
PT sequence useful for e.g. genotyping, comprises depolymerizing the 3'  
PT end of an oligonucleotide probe hybridized to a nucleic acid target  
XX  
PS Claim 47; Page 187; 230pp; English.

XX  
CC The present sequence is an interrogation probe which was used to detect a  
CC segment of the genome of *Campylobacter jejuni*. This was performed as part  
CC of a method for determining the presence of a known exogenous nucleic  
CC acid target sequence in a nucleic acid sample. The method comprises  
CC admixing a treated sample with a depolymerizing enzyme which releases one  
CC or more nucleotides from the 3'-end of a hybridised nucleic acid probe.  
CC The method is used for assaying nucleic acids for a particular native or  
CC mutant sequence, and for genomic typing. It is useful for detecting  
CC mutations, translocations, and single nucleotide polymorphisms,  
CC determination of viral load, species identification, detection of sample  
CC contamination, and analysis of forensic samples. Compared with previous  
CC methods of detecting nucleic acid hybrids, the new method has higher  
CC sensitivity without the need for radiochemicals or electrophoresis. It is  
CC quantitative, highly reproducible and can be automated. The method can  
CC reliably detect as few as 10 copies of a virus in a sample, and is  
CC capable of providing multiple analyses in a single assay (multiplex  
CC assay).  
XX  
SQ Sequence 30 BP; 16 A; 4 C; 5 G; 5 T; 0 other;  
XX  
Query Match 2.7%; Score 26.8; DB 21; Length 30;  
Best Local Similarity 93.3%; Pred. No. 1.3e+03;  
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 289 caagatggtcaaacgttaaaacagaact 318  
Db 1 caagatgcaacaagtttaaaacagaact 30  
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  
RESULT 5  
AAX52169/C  
ID AAX52169 standard; DNA: 50 BP.  
XX  
AC AAX52169;  
XX  
XX 18-JUN-1999 (first entry)  
XX  
DE Synthetic plasmid synlux4 construction oligonucleotide R53.  
XX  
KM DNA plasmid; lux A; lux B; *Vibrio fischeri*; luciferase; promoter;  
KM tng kanamycin/neomycin phosphotransferase; DNA synthesis;  
KM replication competent double-stranded polynucleotide; ss.  
XX  
OS Synthetic.  
XX  
PN WO9914318-A1.  
XX  
PD 25-MAR-1999.  
XX  
PF 16-SEP-1998; 98WO-US19312.  
XX  
PR 16-SEP-1997; 97US-0059017.  
XX  
PA (TEXA ) UNIV TEXAS SYSTEM.  
XX  
PI Evans GA;  
XX  
XX WPI; 1999-244029/20.  
XX  
PT Synthesis of replication competent double-stranded polynucleotides  
PT Example 4; Fig 5E; 135pp; English.  
XX  
XX AAX52021-212 represent oligonucleotide primers that were used to  
CC construct a synthetic DNA plasmid sequence synlux4, to demonstrate the  
CC method of the invention. Within the synlux4 sequence are included the  
CC sequences of lux A, lux B, the A and B components of the *Vibrio fischeri*  
CC luciferase sequence, positions of pUC19 including the origin of  
CC replication and replication stability sequences, and the promoter and  
CC coding sequence for tng kanamycin/neomycin phosphotransferase. The  
CC specification describes a method for the synthesis of replication

CC competent double-stranded polynucleotides. The method comprises  
 CC generating a first set of oligonucleotides corresponding to the plus  
 CC strand and a second set corresponding to the minus strand and  
 CC annealing. The method can be used for preparing polynucleotides  
 CC encoding sequences involved in a biochemical pathway. In particular,  
 CC they can be used to produce polynucleotides encoding enzymes,  
 CC e.g. hexokinase, phosphohexose isomerase, phosphofructokinase-1,  
 CC aldolase, triose-phosphate isomerase, glyceraldehyde-3-phosphate  
 CC dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase,  
 CC enolase or pyruvate kinase. They can also be used for the preparation  
 CC of viral particles, artificial genomes and artificial genetic systems.  
 XX

SQ Sequence 50 BP; 19 A; 8 C; 4 G; 19 T; 0 other;

Query Match 2.1%; Score 21.8; DB 20; Length 50;  
 Best Local Similarity 70.7%; Pred. No. 2.3e+04;  
 Matches 29; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

OY 808 ttaattcagctatcaatgctgtaagaatacaactggtgt 848  
 Db 43 TCATGTCGCCATATTAAAGATGTAAGATATTATGTATAT 3

RESULT 6  
 AAV04223 standard; DNA: 51 BP.

XX AAV04223;

XX 22-JUN-1998 (first entry)

DE Human cardiac troponin I/troponin C 3' PCR primer.

XX Troponin I; troponin C; immunoassay; assay; analysis; human;  
 KM cardiac muscle; skeletal muscle; injury; myocardial infarction;  
 KM diagnosis; HctnI; HctnC; PCR; primer; ss.

OS Synthetic.

OS Homo sapiens.

XX W09739132-A1.

XX 23-OCT-1997.

XX 14-APR-1997; 97NO-US06147.

XX 11-APR-1997; 97US-0833743.

XX 16-APR-1996; 96US-0015772.

XX (UYMI-) UNIV MIAMI.

XX Potter JD;

XX WPI; 1998-062676/06.

XX Immunassay of mammalian troponin using stable standard for

XX comparison - specifically acid-dialysed solution or its lyophilisate

XX used for diagnosis of cardiac or skeletal muscle damage

XX Example 3; Page 34; 94pp; English.

XX This 3' PCR primer was used in the amplification of human cardiac  
 CC troponin I (HctnI) cDNA. It is a complementary sequence encoding  
 CC the C-terminal 8 amino acids of HctnI followed by the N-terminal 8  
 CC amino acids of human cardiac troponin C (HctnC). It was used with  
 CC a vector-based 5' primer in the PCR amplification of HctnI plasmid  
 CC DNA. HctnC DNA was also amplified (see AAV04223), and the PCR  
 CC products were used to construct a polynucleotide (see AAV04225)  
 CC encoding a HctnI/HctnC fusion protein (see AAW41571). The addition  
 CC of the calcium binding protein HctnC to HctnI was made to provide  
 CC more favourable solubility properties. The fusion protein can be  
 CC used as a standard in novel assays of mammalian troponin.

XX SQ Sequence 51 BP; 8 A; 17 C; 9 G; 17 T; 0 other;

Query Match 2.1%; Score 21.4; DB 19; Length 51;  
 Best Local Similarity 71.8%; Pred. No. 2.9e+04;  
 Matches 28; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 505 agattgaacaggttcacaaagtttcttcaggcact 543  
 Db 12 agatgcatcactgctcctcaacttttcttgcggcct 50

RESULT 7  
 AAV04224/c  
 ID AAV04224 standard; DNA: 58 BP.

XX AAV04224;

XX 22-JUN-1998 (first entry)

DE Human cardiac troponin C 5' PCR primer.

XX Troponin C; troponin I; immunoassay; assay; analysis; human;  
 KM cardiac muscle; skeletal muscle; injury; myocardial infarction;  
 KM diagnosis; HctnI; HctnC; PCR; primer; ss.

OS Synthetic.

OS Homo sapiens.

XX W09739132-A1.

XX 23-OCT-1997.

XX 14-APR-1997; 97NO-US06147.

XX 11-APR-1997; 97US-0833743.

XX 16-APR-1996; 96US-0015772.

XX (UYMI-) UNIV MIAMI.

XX Potter JD;

XX WPI; 1998-062676/06.

XX Immunassay of mammalian troponin using stable standard for

XX comparison - specifically acid-dialysed solution or its lyophilisate

XX used for diagnosis of cardiac or skeletal muscle damage

XX Example 3; Page 34; 94pp; English.

XX This 5' PCR primer was used with a vector-based 3' primer in the  
 CC amplification of human cardiac troponin C (HctnC) DNA. Human  
 CC cardiac troponin I (HctnI) DNA was also amplified (see AAV04223) and  
 CC the PCR products were used to construct a polynucleotide (see  
 CC AAV04225) encoding a HctnI/HctnC fusion protein (see AAW41571). The  
 CC addition of the calcium binding protein HctnC to HctnI was made to  
 CC provide more favourable solubility properties. The fusion protein  
 CC can be used as a standard in novel assays of mammalian troponin.

SQ Sequence 58 BP; 18 A; 10 C; 20 G; 10 T; 0 other;

Query Match 2.1%; Score 21.4; DB 19; Length 58;  
 Best Local Similarity 71.8%; Pred. No. 3e+04;  
 Matches 28; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 505 agattgaacaggttcacaaagtttcttcaggcact 543  
 Db 39 AGATGTCATCAGTCCTCTCAAACTTTTCTTGGCGCCT 1

RESULT 8



```

AA97417
ID AA97417 standard; DNA; 54 BP.
XX
XX
AC AA97417;
XX
XX
DT 29-JAN-2001 (first entry)
XX
DE pea wild-type praz2 gene light-repressible promoter oligonucleotide, WT3.
XX
KW GFP-binding protein praz2; pea; light-repressible promoter;
XX photoinhibitory; expression cassette; transgenic plant;
XX deterioration prevention; storage; ss.
XX
OS Pisum sativum.
XX
PN MO200055313-A1.
XX
PD 21-SEP-2000.
XX
PE 03-MAR-2000; 2000MO-JP01269.
XX
PR 12-MAR-1999; 99JP-0066551.
XX
PA (SUNR ) SUNTORX LTD.
XX
PI Sasaki Y, Nagano Y, Inaba T;
XX
DR WPI; 2000-587526/55.
XX
PT New DNA fragment or promoter for expressing a target gene, specifically
PT under photoinhibitory conditions, and for transforming a plant cell or
PT plant to improve quality and prevent deterioration during storage -
XX
PS
XX
XX Example 9; Page 19; 49pp; Japanese.
XX
XX The invention relates to a light-repressible promoter (AA97385), or
CC active fragments thereof (AA97383, AA97384), from the gene encoding
CC the pea GFP-binding protein praz2. The invention also relates to an
CC expression cassette containing the praz2 promoter or its active
CC fragments for the expression of a gene under photoinhibitory or dark
CC conditions in a plant, and to transgenic plants, their descendants
CC and plant tissues comprising the expression cassette. The expression
CC cassette of the invention can be used to generate transgenic plants in
CC which deterioration during storage in the dark is prevented. This is
CC particularly useful for agricultural products. Sequences AA97417-A97418
CC represent oligonucleotides used in an exemplification of the invention
CC to generate a wild-type pea praz2 promoter fragment.
CC
CC Sequence 54 BP; 18 A; 3 C; 12 G; 21 T; 0 other;
XX
XX
XX
XX
XX Query Match 2.1%; Score 21.2; DB 21; Length 54;
XX Best Local Similarity 64.0%; Pred.No.3.3e+04;
XX Matches 32; Conservative 0; Mismatches 18; Indels 0; Gaps 0;
XX
XX 738 tcaagattctgcatcaatgggggtgtatagtagtgattacag 787
XX | | | | | | | | | | | | | | | | | | | | |
XX | | | | | | | | | | | | | | | | | | | | |
XX 1 tggagatttaccagtaattgagattttaccagtaattgagattttacag 50
XX
XX
XX RESULT 9
XX ID AAA27148
XX AAA27148 standard; DNA; 27 BP.
XX
XX AC AAA27148;
XX
XX DT 11-SEP-2000 (first entry)
XX
XX DE Campylobacter coli flaA gene primer flaA-11.
XX
XX Flagellin; flaA; diarrhoea; Guillain-Barre syndrome;
XX vaccine; GBS; PCR primer; ss.
XX
XX

```

[illegible]

PT Campylobacter FlaA protein and coding sequence, useful in reducing  
PT Campylobacter intestinal colonization  
XX  
PS Disclosure; Page 7, 43pp; English.  
XX  
CC The flaA gene encodes the major flagellin subunit of the Campylobacter  
CC coli flagellar filament. Part of the FlaA polypeptide may be fused with  
CC the maltose binding protein of Escherichia coli to make a recombinant  
CC protein. When this protein is introduced into a host an immunological  
CC response is triggered. Therefore the recombinant protein may be used as  
CC a vaccine to protect against C. coli intestinal colonization and the  
CC diarrhoea it causes. This vaccine system is useful as it can  
CC prevent the development of Guillain-Barre syndrome (GBS) which is seen  
CC with whole cell Campylobacter vaccines. The present sequence is the  
CC flaA-2 PCR primer that was used to amplify part of the flaA gene.  
XX  
SQ Sequence 33 BP; 10 A; 8 C; 1 G; 14 T; 0 other:

Query Match 2.1%; Score 21; DB 21; Length 33;  
Best Local Similarity 100.0%; Pred. No. 3.3e+04;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 979 gttaaaatgatgttagat 999  
DB 33 GTTAAATAATGATGTAGAGAT 13

RESULT 11  
AAT60508/C  
ID AAT60508 standard; DNA; 24 BP.  
XX  
AC AAT60508;  
XX  
DT 10-JUN-1997 (first entry)  
XX  
DE Primer CFOAR.4.  
XX  
KW PCR; polymerase chain reaction; amplify; infection; forensic science;  
KW infectious pathogen; genetic disorder; genetic variance; primer; ss.  
XX  
OS Synthetic.  
XX  
PN US5612473-A.  
XX  
PD 18-MAR-1997.  
XX  
PE 16-JAN-1996; 96US-0587209.  
XX  
PR 16-JAN-1996; 96US-0587209.  
XX  
PA (GULL-) GULL LAB.  
PI Coombs J, Glass MJ, Malmstrom SL, Wu L;  
XX WPI; 1997-192163/17.  
DR  
XX  
PT Processing samples for amplification of nucleic acid target  
PT sequences - using extraction buffer containing at least one  
PT detergent and a salt composition of greater than 1 molar  
XX concentration  
XX  
PS Example 3; Column 17; 21pp; English.  
XX  
CC AAT60503-T60514 represent amplification primers for DNA sequences  
CC present in a sample processed by the method of the invention. The  
CC processing method of the invention comprises obtaining a sample of  
CC material potentially containing the target nucleic acid sequences, and  
CC mixing the sample with an external buffer solution. The buffer solution  
CC comprises two detergents, and at least one salt composition present in a  
CC greater than 1 M concentration. The mixture is then centrifuged to obtain  
CC a supernatant portion, which is then heated before being recentrifuged  
CC to precipitate the proteins, and obtaining a second supernatant portion,

CC from which nucleic acids are precipitated. The isolated nucleic acids  
CC are then dissolved. The method provides a rapid means of preparing a  
CC sample for amplification so that multiple analyses can be detected and  
CC differentiated within a relatively short time period (typically less  
CC than 5 hours with the novel pre-processing step taking less than 5  
CC minutes). Typical applications of nucleic acid amplification include  
CC detection of infections in patients, foodstuffs and for  
CC diagnostic/forensic or quality control purposes, to discriminate between  
CC multiple potential infectious pathogens, to diagnose genetic disorders or  
CC to identify genetic variances.  
XX  
SQ Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other:

Query Match 2.1%; Score 20.8; DB 18; Length 24;  
Best Local Similarity 91.7%; Pred. No. 3.4e+04;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 91 gttcttagaatcaactcgcagca 114  
DB 24 GGTCTTAGAATTAACCTCAGCAGCA 1

RESULT 12  
AAV31446/C  
ID AAV31446 standard; DNA; 24 BP.  
XX  
AC AAV31446;  
XX  
DT 11-AUG-1998 (first entry)  
XX  
DE Campylobacter nucleic acid sequence amplifying primer CFOAR.  
XX  
KW Salmonella; microorganism; detection; multiple analyte; PCR primer;  
KW Yersinia; Escherichia coli; Campylobacter; ss.  
XX  
OS Synthetic.  
XX  
PN US5756701-A.  
XX  
PD 26-MAY-1998.  
XX  
PE 06-AUG-1996; 96US-0692725.  
XX  
PR 16-JAN-1996; 96US-0587209.  
XX  
PR 06-AUG-1996; 96US-0692725.  
XX  
PA (GULL-) GULL LAB INC.  
PI Coombs J, Glass MJ, Malmstrom SL, Wu L;  
XX WPI; 1998-321634/28.  
DR  
XX  
PT Nucleic acid probes and primers - for detecting Salmonella, Yersinia  
PT or E. coli  
XX  
PS Claim 5; Column 17; 21pp; English.  
XX  
CC This primer is used for the PCR amplification of Campylobacter nucleic  
CC acid sequences. The invention provides nucleic acid probes and primers  
CC for detecting Salmonella, Yersinia or E. coli. It provides methods and  
CC apparatus for detecting and discriminating multiple analytes within a  
CC test sample. The methods are simple, user-friendly, cost effective and  
CC fast. The methods and the probes and primer sequences are used for  
CC detecting the corresponding microorganisms in clinical samples.  
XX  
SQ Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other:

Query Match 2.1%; Score 20.8; DB 19; Length 24;  
Best Local Similarity 91.7%; Pred. No. 3.4e+04;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 91 ggtcttagaactcaactcgcagca 114  
 |||||  
 Db 24 GGTCTTAGAATTAACTCAGCAGCA 1

RESULT 13  
 AAV25942/c  
 ID AAV25942 standard; DNA: 24 BP.  
 XX  
 AC AAV25942;  
 XX  
 DT 15-JUL-1998 (first entry)  
 XX  
 DE Oligonucleotide PCR primer CFO4R gene.  
 XX  
 KM Sequence-specific probe: enterohaemorrhagic; *Escherichia coli*;  
 KM *Salmonella*; *Campylobacter*; *Shigella*; *Yersinia*; beta-globin;  
 KM *gastroenteritis*; PCR primer; ss.  
 XX  
 OS Synthetic.  
 OS *Campylobacter* sp.  
 XX  
 PN US5753444-A.  
 PD 19-MAY-1998.  
 PF 07-AUG-1996; 96US-0689235.  
 PR 16-JAN-1996; 96US-0587209.  
 PR 07-AUG-1996; 96US-0689235.  
 XX  
 PA (GULL-) GULL LAB INC.  
 XX  
 PI Coombs J, Glass MJ, Malmstrom SL, Wu L;  
 DR WPI; 1998-311393/27.  
 XX  
 PT Distinguishing between similar nucleic acid samples - using  
 PT sequence-specific probes e.g. between enterohaemorrhagic and normal  
 PT *Escherichia coli*  
 XX  
 PS Example 3; Column 17; 21pp; English.  
 CC The present sequence represents a PCR primer used in an example of the  
 CC present invention. The present invention describes a method for  
 CC detecting mismatches between first and second nucleic acid sequences  
 CC having at least one base difference. The method comprises: (a) obtaining  
 CC at least one labelled probe consisting of an oligonucleotide sequence  
 CC spanning the location of at least one base difference between the first  
 CC and second sequences, where the oligonucleotide sequence contains at  
 CC least one neutral base molecule in a position other than the position of  
 CC the base difference(s) but is otherwise exactly complementary to the  
 CC first sequence, so that the probe hybridises more weakly with the second  
 CC sequence than with the first sequence; (b) mixing the probe(s) with the  
 CC first and second sequences under hybridisation conditions; (c)  
 CC dissociating any probe/second sequence hybrids; and (d) detecting  
 CC probe/first sequence hybrids. The method can be used to distinguish  
 CC between similar DNA/RNA sequences in a sample, especially to distinguish  
 CC enterohaemorrhagic *E. coli* O157:H7 from other *E. coli* strains e.g. in  
 CC stool samples from people suffering from gastroenteritis, caused  
 CC specifically by enterohaemorrhagic *E. coli*. Use of the method shortens  
 CC the time between sample preparation to obtaining results, than has been  
 CC possible with previous similar procedures.  
 XX  
 SO Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;

Query Match 2.1%; Score 20.8; DB 19; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3.4e+04;  
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 91 ggtcttagaactcaactcgcagca 114

Db 24 GGTCTTAGAATTAACTCAGCAGCA 1  
 |||||

RESULT 14  
 AAV20847/c  
 ID AAV20847 standard; DNA: 24 BP.  
 XX  
 AC AAV20847;  
 XX  
 DT 01-JUL-1998 (first entry)  
 XX  
 DE *Campylobacter* CFO4R gene PCR primer.  
 XX  
 KM *Escherichia coli* strain O157:H7; detection; microorganism; infection;  
 KM enterohaemorrhagic; PCR primer; ss.  
 XX  
 OS Synthetic.  
 OS *Campylobacter* sp.  
 XX  
 PN US5738995-A.  
 PD 14-APR-1998.  
 PF 07-AUG-1996; 96US-0689236.  
 PR 16-JAN-1996; 96US-0587209.  
 PR 07-AUG-1996; 96US-0689236.  
 XX  
 PA (GULL-) GULL LAB INC.  
 XX  
 PI Coombs J, Glass MJ, Malmstrom SL, Wu L;  
 DR WPI; 1998-26031/23.  
 XX  
 PT Probes for detecting *Escherichia coli* strain O157:H7 - useful for  
 PT diagnosis of enterohaemorrhagic *Escherichia coli* infection(s)  
 XX  
 PS Example 3; Column 17; 21pp; English.  
 CC The present sequence represents a PCR primer used in an example of the  
 CC present invention. The present invention describes probes used in the  
 CC detection of *Escherichia coli* strain O157:H7 in a sample. The method of  
 CC detection comprises: (a) obtaining at least 1 probe specifically given  
 CC in the specification, labelled with a label that permits probe detection  
 CC when hybridised to a complementary nucleic acid sequence which is  
 CC specific for a nucleic acid sequence of the microorganism; (b)  
 CC hybridising the probes and the sample, and (c) detecting hybrids  
 CC comprising the probes and the nucleic acid sequences. The method and  
 CC probes may be used for diagnosis of enterohaemorrhagic *E. coli*  
 CC infections. The methods and the materials permit the detection and  
 CC discrimination of multiple analyses.  
 XX  
 SO Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;

Query Match 2.1%; Score 20.8; DB 19; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3.4e+04;  
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 91 ggtcttagaactcaactcgcagca 114  
 |||||  
 Db 24 GGTCTTAGAATTAACTCAGCAGCA 1

RESULT 15  
 AAF16711  
 ID AAF16711 standard; DNA: 44 BP.  
 XX  
 AC AAF16711;  
 DT 09-MAR-2001 (first entry)

DE	dGMP-specific aptamer clone #19.	
XX		
KM	Polymeric biomolecule; aptamer; ss.	
XX		
OS	Synthetic.	
XX		
PN	WO200071755-A2.	
XX		
PD	30-NOV-2000.	
XX		
PF	25-MAY-2000; 2000WO-US14401.	
XX		
PR	25-MAY-1999; 99US-0135863.	
XX		
PA	(PRAE-) PRAELUX INC.	
XX		
PI	Kwagh J, Macklin JI, Mltis PG, Uimer KM;	
XX		
DR	WPI; 2001-016410/02.	
XX		
PT	Sequencing a polymeric biomolecule, such as a polynucleotide,	
PT	polysaccharide or polypeptide, comprises separating a terminal monomer	
PT	from the polymeric biomolecule and identifying the separated terminal	
PT	monomer using an aptamer -	
XX		
PS	Claim 37; Fig 15; 123pp; English.	
XX		
CC	The present invention relates to a new method for sequencing a	
CC	polymeric biomolecule. The method involves separating a terminal	
CC	monomer from the polymeric biomolecule and identifying the separated	
CC	terminal monomer using an aptamer. The method is useful for	
CC	sequencing or structurally characterizing a polymeric biomolecule	
CC	such as a polynucleotide, a polysaccharide or a polypeptide. The	
CC	method is also useful for developing aptamers.	
XX		
SO	Sequence 44 BP; 9 A; 6 C; 19 G; 10 T; 0 other;	
QY	Query Match 2.1%; Score 20.8; DB 22; Length 44;	
	Best Local Similarity 70.0%; Pred. No. 3.9e+04;	
DB	Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;	
	747 tgcatacaatgggtgtgtataggaagtgtatattca 786	
	4 tgcaccactgggctgggtacgtgtaggtgtcgaattca 43	

Search completed: April 17, 2002, 02:17:16  
Job time: 3512 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 17, 2002, 01:23:59 ; Search time 86.97 Seconds

(without alignments)  
2601.489 Million cell updates/sec

Title: US-09-439-311-1

Perfect score: 999

Sequence: 1 attacacaaatgtgtcagc.....ttaaaatgatgtagatagat 999

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 351203 seqs, 113238999 residues

Total number of hits satisfying chosen parameters: 515962

Minimum DB seq length: 0  
Maximum DB seq length: 60

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued\_Patents\_NA:\*  
1: /cgn2\_6/prodata/2/lna/5A.COMB.seq:\*  
2: /cgn2\_6/prodata/2/lna/5B.COMB.seq:\*  
3: /cgn2\_6/prodata/2/lna/6A.COMB.seq:\*  
4: /cgn2\_6/prodata/2/lna/6B.COMB.seq:\*  
5: /cgn2\_6/prodata/2/lna/ECTUS.COMB.seq:\*  
6: /cgn2\_6/prodata/2/lna/backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	26.8	2.7	30	4	US-09-358-972-102
C 2	26.8	2.7	30	4	US-09-358-972-103
C 3	26.8	2.7	30	4	US-09-406-147-32
C 4	26.8	2.7	30	4	US-09-406-147-34
C 5	20.8	2.1	24	1	US-08-587-209-6
C 6	20.8	2.1	24	1	US-08-689-236-6
C 7	20.8	2.1	24	1	US-08-689-236-6
C 8	20.8	2.1	24	1	US-08-692-725-6
C 9	20.8	2.1	24	2	US-08-692-726-6
C 10	20.8	2.1	58	2	US-08-431-527A-7
C 11	20.8	2.1	58	4	US-09-214-278-30
C 12	20.6	2.1	52	3	US-08-886-967-3
C 13	20.6	2.1	52	4	US-09-306-949-3
C 14	20.6	2.1	59	3	US-08-874-825-118
C 15	20.6	2.0	50	2	US-08-450-905B-7
C 16	20.6	2.0	50	3	US-07-982-759F-7
C 17	20.6	2.0	57	1	US-08-141-892A-4
C 18	20.6	2.0	57	2	US-08-583-447A-4
C 19	20.6	2.0	57	2	US-08-467-920-4
C 20	20.6	2.0	57	3	US-08-635-930-4
C 21	20.6	2.0	57	3	US-09-193-997-4
C 22	20.6	2.0	57	4	US-09-138-237A-4
C 23	20.6	2.0	60	1	US-08-478-370-4
C 24	19.6	2.0	43	1	US-07-959-946-12
C 25	19.6	2.0	43	1	US-08-333-577-12
C 26	19.6	2.0	43	5	PCT-US92-08634-12
C 27	19.6	2.0	58	1	US-08-105-483-174

C 28	19.6	2.0	58	1	US-08-709-209-174	Sequence 174, App
C 29	19.6	2.0	58	1	US-08-303-275-62	Sequence 62, App1
C 30	19.6	2.0	58	1	US-08-458-101-174	Sequence 174, App
C 31	19.6	2.0	60	1	US-07-670-296-19	Sequence 19, App1
C 32	19.6	2.0	60	1	US-08-093-781-20	Sequence 20, App1
C 33	19.6	2.0	60	3	US-08-963-602-2	Sequence 2, App1
C 34	19.4	1.9	37	2	US-08-403-853-8	Sequence 8, App1
C 35	19.4	1.9	60	1	US-08-487-890A-127	Sequence 127, App
C 36	19.4	1.9	60	2	US-08-478-435-127	Sequence 127, App
C 37	19.4	1.9	60	2	US-08-337-483-127	Sequence 127, App
C 38	19.4	1.9	60	2	US-08-478-373-127	Sequence 127, App
C 39	19.4	1.9	60	3	US-08-474-671-127	Sequence 127, App
C 40	19.4	1.9	60	3	US-08-483-577A-127	Sequence 127, App
C 41	19.4	1.9	60	4	US-08-897-438-127	Sequence 127, App
C 42	19.2	1.9	58	2	US-08-431-527A-6	Sequence 6, App1
C 43	19.2	1.9	60	1	US-07-609-716-72	Sequence 72, App1
C 44	19.2	1.9	60	3	US-08-475-411A-72	Sequence 72, App1
C 45	19.2	1.9	60	4	US-08-478-029A-72	Sequence 72, App1

#### ALIGNMENTS

```

RESULT 1
US-09-358-972-102/c
; Sequence 102, Application US/09358972
; Patent No. 6235480
; GENERAL INFORMATION:
; APPLICANT: Shultz, John W
; APPLICANT: Lewis, Martin K.
; APPLICANT: Liepp, Donna
; APPLICANT: Mandrekar, Michelle
; APPLICANT: Kephart, Daniel
; APPLICANT: Rhodes, Richard B.
; APPLICANT: Andrews, Christine A.
; APPLICANT: Hartnett, James R.
; APPLICANT: Gu, Trent
; APPLICANT: Olson, Ryan J.
; APPLICANT: Wood, Keith W.
; APPLICANT: Welch, Roy
; TITLE OF INVENTION: Nucleic Acid Detection
; FILE REFERENCE: Pro-103 6868/75528
; CURRENT APPLICATION NUMBER: US/09/358, 972
; CURRENT FILING DATE: 1999-07-22
; EARLIER APPLICATION NUMBER: 09/252, 436
; EARLIER FILING DATE: 1999-02-18
; EARLIER APPLICATION NUMBER: 09/042, 287
; EARLIER FILING DATE: 1998-03-13
; NUMBER OF SEQ ID NOS: 290
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 102
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Campylobacter jejuni
; FEATURE:
; OTHER INFORMATION: probe to Campylobacter jejuni
US-09-358-972-102

Query Match      2.7%; Score 26.8; DB 4; Length 30;
Best local Similarity 93.3%; Pred. No. 82;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 289 caagatgtctaaagcttaaaacagaact 318
      ||||||| ||||| ||||||| |||||||
DB 30 CAAGATGACAAAGTTTAAAAACAAGACT 1

RESULT 2
US-09-358-972-103
; Sequence 103, Application US/09358972
; Patent No. 6235480
; GENERAL INFORMATION:

```

```

: APPLICANT: Shultz, John W
: APPLICANT: Lewis, Martin K.
: APPLICANT: Lieppe, Donna
: APPLICANT: Mandrekar, Michelle
: APPLICANT: Kephart, Daniel
: APPLICANT: Rhodes, Richard B.
: APPLICANT: Andrews, Christine A.
: APPLICANT: Hartnett, James R.
: APPLICANT: Gu, Trent
: APPLICANT: Olson, Ryan J.
: APPLICANT: Wood, Keith W.
: APPLICANT: Welch, Roy
: TITLE OF INVENTION: Nucleic Acid Detection
: FILE REFERENCE: Pro-103 6868/75528
: CURRENT APPLICATION NUMBER: US/09/358,972
: CURRENT FILING DATE: 1999-07-22
: EARLIER APPLICATION NUMBER: 09/252,436
: EARLIER FILING DATE: 1999-02-18
: EARLIER APPLICATION NUMBER: 09/042,287
: EARLIER FILING DATE: 1998-03-13
: NUMBER OF SEQ ID NOS: 290
: SOFTWARE: Patentln Ver. 2.0
: SEQ ID NO 103
: LENGTH: 30
: TYPE: DNA
: ORGANISM: Campylobacter jejuni
: FEATURE:
: OTHER INFORMATION: probe to Campylobacter jejuni
US-09-358-972-103
```

```

Query Match          2.7%: Score 26.8; DB 4; Length 30;
Best Local Similarly 93.3%: Pred. No. 82;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 289 caagatggtcaagcttaaaacaagaact 318
Db 1 caagatgacacaagtttaaaacaagaact 30
```

```

RESULT 3
US-09-406-147-32/c
: Sequence 32, Application US/09406147
: Patent No. 6270974
: GENERAL INFORMATION:
: APPLICANT: Shultz, John W
: APPLICANT: Lewis, Martin K
: APPLICANT: Lieppe, Donna
: APPLICANT: Mandrekar, Michelle
: APPLICANT: Kephart, Daniel
: APPLICANT: Rhodes, Richard B
: APPLICANT: Andrews, Christine A
: APPLICANT: Hartnett, James R
: APPLICANT: Gu, Trent
: APPLICANT: Wood, Keith V
: APPLICANT: Welch, Roy
: TITLE OF INVENTION: EXOGENOUS NUCLEIC ACID DETECTION
: FILE REFERENCE: EXOGENOUS NUCLEIC ACID DETECTION
: CURRENT APPLICATION NUMBER: US/09/406,147
: CURRENT FILING DATE: 1999-09-27
: EARLIER APPLICATION NUMBER: 09/252,436
: EARLIER FILING DATE: 1999-02-18
: EARLIER APPLICATION NUMBER: 09/042,287
: EARLIER FILING DATE: 1998-03-13
: NUMBER OF SEQ ID NOS: 92
: SOFTWARE: Patentln Ver. 2.0
: SEQ ID NO 32
: LENGTH: 30
: TYPE: DNA
: ORGANISM: Campylobacter jejuni
US-09-406-147-32
```

```

Query Match          2.7%: Score 26.8; DB 4; Length 30;
Best Local Similarly 93.3%: Pred. No. 82;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 289 caagatggtcaagcttaaaacaagaact 318
Db 30 CAAGATGACACAAGTTTAAACAGAAGACT 1
```

```

RESULT 4
US-09-406-147-34
: Sequence 34, Application US/09406147
: Patent No. 6270974
: GENERAL INFORMATION:
: APPLICANT: Shultz, John W
: APPLICANT: Lewis, Martin K
: APPLICANT: Lieppe, Donna
: APPLICANT: Mandrekar, Michelle
: APPLICANT: Kephart, Daniel
: APPLICANT: Rhodes, Richard B
: APPLICANT: Andrews, Christine A
: APPLICANT: Hartnett, James R
: APPLICANT: Gu, Trent
: APPLICANT: Wood, Keith V
: APPLICANT: Welch, Roy
: TITLE OF INVENTION: EXOGENOUS NUCLEIC ACID DETECTION
: FILE REFERENCE: EXOGENOUS NUCLEIC ACID DETECTION
: CURRENT APPLICATION NUMBER: US/09/406,147
: CURRENT FILING DATE: 1999-09-27
: EARLIER APPLICATION NUMBER: 09/252,436
: EARLIER FILING DATE: 1999-02-18
: EARLIER APPLICATION NUMBER: 09/042,287
: EARLIER FILING DATE: 1998-03-13
: NUMBER OF SEQ ID NOS: 92
: SOFTWARE: Patentln Ver. 2.0
: SEQ ID NO 34
: LENGTH: 30
: TYPE: DNA
: ORGANISM: Campylobacter jejuni
US-09-406-147-34
```

```

Query Match          2.7%: Score 26.8; DB 4; Length 30;
Best Local Similarly 93.3%: Pred. No. 82;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 289 caagatggtcaagcttaaaacaagaact 318
Db 1 caagatgacacaagtttaaaacaagaact 30
```

```

RESULT 5
US-08-587-209-6/c
: Sequence 6, Application US/08587209
: Patent No. 5612473
: GENERAL INFORMATION:
: APPLICANT: Wu, Linxian
: APPLICANT: Coombs, Jana
: APPLICANT: Malmstrom, Sharon L.
: APPLICANT: Glass, Michael J.
: TITLE OF INVENTION: Methods and Apparatus for Preparing, Amplifying,
: TITLE OF INVENTION: and Discriminating Multiple Analyses
: NUMBER OF SEQUENCES: 30
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: David O. Seeley, Esq.
: ADDRESSEE: Workman, Nydegger & Seeley
: STREET: 1000 Eagle Gate Tower
: STREET: 60 East South Temple
: CITY: Salt Lake City
: STATE: Utah
: COUNTRY: USA
: ZIP: 84111
: COMPUTER READABLE FORM:
```

MEDIUM TYPE: Diskette, 3.50 inch,  
MEDIUM TYPE: 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: Wordperfect 6.0a for WINDOWS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/587,209  
FILING DATE: 16-JAN-1996  
CLASSIFICATION: 435  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 24 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-587-209-6

Query Match 2.1%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 3e+03;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 91 ggtcttagaactcaactccgcagca 114  
|||||  
DB 24 GGCTTAGAATTAACACGACGA 1

RESULT 6  
US-08-689-236-6/C  
Sequence 6, Application US/08689236  
Patent No. 5738995  
GENERAL INFORMATION:  
APPLICANT: Wu, Linxian  
APPLICANT: Coombs, Jana  
APPLICANT: Malmstrom, Sharon L.  
APPLICANT: Glass, Michael J.  
TITLE OF INVENTION: Methods and Apparatus for  
TITLE OF INVENTION: Preparing, Amplifying, and Discriminating Multiple Analyses  
NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: David O. Seeley, Esq.  
ADDRESSEE: Workman, Nydegger & Seeley  
STREET: 1000 Eagle Gate Tower  
STREET: 60 East South Temple  
CITY: Salt Lake City  
STATE: Utah  
COUNTRY: USA  
ZIP: 84111  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch,  
MEDIUM TYPE: 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: Wordperfect 6.0a for WINDOWS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/689,236  
FILING DATE: 16-JAN-1996  
CLASSIFICATION: 435  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 24 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-689-236-6

Query Match 2.1%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 3e+03;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 91 ggtcttagaactcaactccgcagca 114  
|||||  
DB 24 GGCTTAGAATTAACACGACGA 1

RESULT 7  
US-08-689-235-6/C  
Sequence 6, Application US/08689235  
Patent No. 5753444  
GENERAL INFORMATION:  
APPLICANT: Wu, Linxian  
APPLICANT: Coombs, Jana  
APPLICANT: Malmstrom, Sharon L.  
APPLICANT: Glass, Michael J.  
TITLE OF INVENTION: Methods and Apparatus for  
TITLE OF INVENTION: Preparing, Amplifying, and Discriminating Multiple Analyses  
NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: David O. Seeley, Esq.  
ADDRESSEE: Workman, Nydegger & Seeley  
STREET: 1000 Eagle Gate Tower  
STREET: 60 East South Temple  
CITY: Salt Lake City  
STATE: Utah  
COUNTRY: USA  
ZIP: 84111  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch,  
MEDIUM TYPE: 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: Wordperfect 6.0a for WINDOWS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/689,235  
FILING DATE: 16-JAN-1996  
CLASSIFICATION: 435  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 24 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-689-235-6

Query Match 2.1%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 3e+03;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 91 ggtcttagaactcaactccgcagca 114  
|||||  
DB 24 GGCTTAGAATTAACACGACGA 1

RESULT 8  
US-08-692-725-6/C  
Sequence 6, Application US/08692725  
Patent No. 5756701  
GENERAL INFORMATION:  
APPLICANT: Wu, Linxian  
APPLICANT: Coombs, Jana  
APPLICANT: Malmstrom, Sharon L.  
APPLICANT: Glass, Michael J.  
TITLE OF INVENTION: Methods and Apparatus for  
TITLE OF INVENTION: Preparing, Amplifying, and Discriminating Multiple Analyses  
NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: David O. Seeley, Esq.  
ADDRESSEE: Workman, Nydegger & Seeley  
STREET: 1000 Eagle Gate Tower  
STREET: 60 East South Temple  
CITY: Salt Lake City

MOLECULE TYPE: DNA;

APPLICANT.

```

RESULT 11
US-09-214-278-30/C
; Sequence 30, Application US/09214278
; Patient No. 6291210
; GENERAL INFORMATION:
; APPLICANT: Sakano, Setji
; APPLICANT: Itoh, Akira

```



Query Match	2.18;	Score	20.6;	DB	3;	Length	52;
Best Local Similarity	67.48;	Pred. No.	4.6e+03;				

RESULT 14  
US-08-874-825-118/c  
; Sequence 118, Application US/08874825  
; Patent No. 6057101  
; GENERAL INFORMATION:  
; APPLICANT: Nandabalan, Krishnan  
; APPLICANT: Rothberg, Jonathan

APPLICANT: Yang, Meljia  
APPLICANT: Knight, James  
TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF  
TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS  
TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS  
NUMBER OF SEQUENCES: 122  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Penile & Edmonds  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10036/2711  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/874,825  
FILING DATE: 13-JUN-1997  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/663,824  
FILING DATE: 14-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Mirock, S. Leslie  
REGISTRATION NUMBER: 18,872  
REFERENCE/DOCKET NUMBER: 7934-045  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-790-9090  
TELEFAX: 212-869-8864  
TELEX: 66141 PENNIE  
INFORMATION FOR SEQ ID NO: 118:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 39 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-874-825-118

Query Match 2.0%; Score 20; DB 3; Length 39;  
Best Local Similarity 82.1%; Pred. No. 6e+03;  
Matches 23; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

OY 768 aggtgaagtgatcatcagatggtgat 795  
|||||  
DB 39 AGGTCAGGTGCTTCTCAGATGCTCAT 12

RESULT 15  
US-08-450-905B-7/c  
Sequence 7, Application US/08450905B  
Patent No. 5856301  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: Stem Cell Inhibiting Proteins  
NUMBER OF SEQUENCES: 178  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: HALE and DORR  
STREET: 60 State Street  
CITY: Boston  
STATE: MA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/450,905B  
FILING DATE: 26-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/982,759  
FILING DATE: 08-MAR-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9127319.3  
FILING DATE: 23-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9221587.0  
FILING DATE: 14-OCT-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: BAKER, HOLIE L.  
REGISTRATION NUMBER: 31,321  
REFERENCE/DOCKET NUMBER: 102,378,120DV-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-526-6110  
TELEFAX: 617-526-5000  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 50 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
FEATURE:  
NAME/KEY: misc.feature  
LOCATION: 1..50  
OTHER INFORMATION: /product- "OLIGOMER FOR  
OTHER INFORMATION: CONSTRUCTION OF SYNTHETIC LD78 GENE"  
US-08-450-905B-7

Query Match 2.0%; Score 20; DB 2; Length 50;  
Best Local Similarity 72.2%; Pred. No. 6.6e+03;  
Matches 26; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

OY 368 caaatccacttcattatgcaacaacttta 403  
|||||  
DB 36 CAAATTCACMAAATTCATGCTGACTACTTGAA 1

Search completed: April 17, 2002, 02:18:56  
Job time: 3297 sec

Wed Apr 17 07:36:45 2002

us-09-439-311-1.rml

---

THIS PAGE BLANK (USPTO)

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 17, 2002, 01:16:14 : Search time 1464.96 Seconds  
(without alignments)  
7327.868 Million cell updates/sec

Title: US-09-439-311-1

Perfect score: 999  
Sequence: 1 attacacaaatgttcgacg.....ttaaaatgctgtagatagat 999

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 11351937 seqs, 5372889281 residues

Total number of hits satisfying chosen parameters: 111874

Minimum DB seq length: 0  
Maximum DB seq length: 60

Post-processing: Maximum Match 0%  
Listing first 45 summaries

Database :

EST:\*  
1: em\_estfun:\*  
2: em\_esthum:\*  
3: em\_estin:\*  
4: em\_estom:\*  
5: em\_estpl:\*  
6: em\_estba:\*  
7: em\_estro:\*  
8: em\_estov:\*  
9: em\_hic:\*  
10: gp\_estl:\*  
11: gp\_estl2:\*  
12: gp\_hic:\*  
13: gp\_gss:\*  
14: em\_gss\_fun:\*  
15: em\_gss\_hum:\*  
16: em\_gss\_inu:\*  
17: em\_gss\_pln:\*  
18: em\_gss\_pro:\*  
19: em\_gss\_rtd:\*  
20: em\_gss\_vrt:\*  
21: em\_gss\_other:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	23.6	2.4	50	10	AU104183	AU104183 AU104183
2	21.6	2.2	50	10	AA608932	AA608932 af03d01.s
3	21.21	2.1	52	10	AA122474	AA122474 mg27h10.r
4	20.8	2.1	59	10	AM687832	AM687832 NF01A01R
5	20.8	2.1	59	10	BF638864	BF638864 NF06H02P
6	20.6	2.1	58	10	AA874675	AA874675 vW84C07.r
7	20.4	2.0	51	13	A2812517	A2812517 2M0079C15
8	20.4	2.0	55	10	AU014315	AU014315 AU014315
9	20.2	2.0	50	10	AU103731	AU103731 AU103731
10	20.2	2.0	54	13	A2954544	A2954544 2M0220G15
11	20.2	2.0	58	11	BF131272	BF131272 601819529
12	20.2	2.0	59	11	W38842	W38842 zb28c08.r1

13	20	2.0	54	13	A2434413	A2434413 IM0220118
14	20	2.0	56	10	AM780772	AM780772 s185c06.y
15	20	2.0	56	13	AF149647	AF149647 AF149647.y
16	20	2.0	56	13	A2451302	A2451302 IM0250012
17	20	2.0	58	10	AA164130	AA164130 mq84f08.r
18	20	2.0	60	10	AA878830	AA878830 of83f08.s
19	20	2.0	60	13	A2778864	A2778864 2M0014P24
20	20	2.0	60	13	B44939	B44939 HS-1060-A2-
21	19.8	2.0	58	11	BC939021	BC939021 cn30a04.y
22	19.8	2.0	58	11	BC058837	BC058837 nag43c06.
23	19.8	2.0	60	10	AU060311	AU060311 AU060311
24	19.6	2.0	50	13	A2397298	A2397298 IM0162A13
25	19.6	2.0	54	10	AM307272	AM307272 sf54h07.y
26	19.6	2.0	59	13	A2626633	A2626633 IM0467C04
27	19.4	1.9	50	10	AU107058	AU107058 AU107058
28	19.4	1.9	52	10	AM687820	AM687820 NF013G12R
29	19.4	1.9	53	11	BG370297	BG370297 na129h10.
30	19.4	1.9	56	13	AM513614	AM513614 xo47d06.x
31	19.4	1.9	56	13	A2608724	A2608724 IM0433C09
32	19.4	1.9	58	10	AA190288	AA190288 mt93a05.r
33	19.4	1.9	58	11	T18527	T18527 hbc2089 Hum
34	19.4	1.9	58	11	T18565	T18565 hbc2087 Hum
35	19.4	1.9	59	10	A1855540	A1855540 sc20e08.y
36	19.2	1.9	51	11	D18206	D18206 MUGS00476
37	19.2	1.9	52	10	AA492773	AA492773 v176h09.x
38	19.2	1.9	54	13	A2783521	A2783521 2M0025P17
39	19	1.9	50	11	BG271613	BG271613 na159h03.
40	19	1.9	52	10	AM396361	AM396361 sh27b06.y
41	19	1.9	53	11	BG408927	BG408927 g83c07.y
42	19	1.9	54	13	A2345736	A2345736 HM080M03
43	19	1.9	60	11	C01215	C01215 HUMGS000792
44	19	1.9	60	11	BF638586	BF638586 NE054G03P
45	18.8	1.9	50	10	AU104948	AU104948 AU104948

#### ALIGNMENTS

RESULT 1  
AU104183/c  
LOCUS  
DEFINITION  
AU104183 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
KAT06093, mRNA sequence.  
ACCESSION  
AU104183  
VERSION  
AU104183.1 GI:13553704  
KEYWORDS  
EST.  
SOURCE  
human.  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1 (bases 1 to 50)  
Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Hata  
,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S., Okudo  
,K., Suyama,A. and Sugano,S.  
Fine Structural analysis of transcription start sites of human  
mRNAs using full-length enriched and 5'-end enriched cDNA libraries  
unpublished (2001)  
JOURNAL  
Contact: Yutaka Suzuki  
Department of Virology  
Institute of Medical Science, University of Tokyo  
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
Email: yusuzuki@ims.u-tokyo.ac.jp  
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano  
,S. Construction and characterization of a full length-enriched and  
a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).  
FEATURES  
source  
1. 50  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="KAT06093"  
/clone\_lib="Sugano Homo sapiens cDNA library"  
BASE COUNT  
12 a 12 c 4 g 22 t  
ORIGIN



JOURNAL  
COMMENT

Unpublished (2000)  
Contact: Harrison MJ  
Plant Biology Division  
The Samuel Roberts Noble Foundation  
2510 Sam Noble Parkway, Ardmore, OK 73402, USA  
Tel: 580 221 7325  
Fax: 580 221 7380  
Email: mjharrison@noble.org  
Insert Length: 60 Std Error: 0.00  
Plate: 060 Row: H Column: 02  
Seq primer: TCACACGAGAAACGCATGTCAC.  
Location/Qualifiers

FEATURES  
source

1..60  
/organism="Medicago truncatula"  
/db\_xref="taxon:3880"  
/clone="NF06H02PL"  
/clone\_1lb="Phosphate starved leaf"  
/tissue-type="leaf"  
/dev\_stage="trifoliolate"  
/note="Vector: lambda Zap; At the trifoliolate stage, M. truncatula plants were transplanted to phosphate-free sand and grown for a further 30 days. During this 30 day period, the plants were fertilized twice weekly with 1/2 Hoaglands solution containing only 20mM potassium phosphate. RNA was prepared from above ground tissues."

BASE COUNT  
ORIGIN

15 a 17 c 12 g 9 t 7 others

Query Match 2.1% Score 20.8; DB 11; Length 60;  
Best Local Similarity 59.6%; Pred. No. 6.9e+05;  
Matches 28; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 76 tcaagactcagcttcaggcttagaatcacacccgacgcagatgatgc 122  
||| ||| ||| ||| ||| | ||| | | | |||  
Db 47 TCAGAGACTNNGTNAGCTTTGATGGNCAGCCTANMCNGTGCCTGCGC 1

RESULT 6  
AA874675/c  
LOCUS  
DEFINITION  
IMAGE:1261644 5' similar to TR:003713 003713 CYTOCHROME B ;, mRNA sequence.

AA874675 58 bp mRNA EST 19-MAR-1998  
AA874675 AA874675.1 GI:2978571  
EST.

SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

Mus musculus.  
Mus musculus.  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murine; Mus. 1 (bases 1 to 58)  
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T., Schellenberg,K., Stepien,M., Tan,F., Underwood,K., Moore,B., Theisinger,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Waterston,R.  
The WashU-HMI Mouse EST Project  
Unpublished (1996)  
Contact: Marra M/Mouse EST Project  
WashU-HMI Mouse EST Project  
Washington University School of Medicine  
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.edu  
This clone is available royalty-free through LNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:664196  
Trace considered overall poor quality  
Possible reversed clone: similarity on wrong strand  
Seq primer: -26ml3 rev1 ET from Amersham  
High quality sequence stop: 1.









```

/db_xref="taxon:10090"
/clone="UGC1M0220118"
/clone_lib="Mouse 10kb plasmid UGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PMD42nv: Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g1147321141gb1AFL29072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match 2.0% Score 20; DB 13; Length 54;  
 Best Local Similarity 61.5% Pred. No. 1,1e+06;  
 Matches 32; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 836 atcaacacgcyggtccaagcctcaagaatgaaatgtaactgtctcttac 887  
 |||||  
 Db 2 attcaaaatgcctttatgctctcaaaaatgtaaaatgaaatgtaactgtctcaac 53  
 |||||

RESULT	14
AM780772	
LOCUS	AM780772 56 bp mRNA
DEFINITION	s185c6.72 Gm-cl037 Glycine max cDNA clone GENOME SYSTEMS CLONE ID: Gm-cl037-803 5', mRNA sequence.
ACCESSION	AM780772
VERSION	AM780772.1 GI:7795447
KEYWORDS	EST.
SOURCE	soybean.
ORGANISM	Glycine max

REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
1 (bases 1 to 56)	Shoemaker, R., Kelm, P., Vodkin, L., Erpellding, J., Coryell, V., Khanna, A., Bolla, B., Marras, M., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, T., Underwood, K., Steptoe, M., Theising, B., Allen, M., Bowers, Y., Pearson, B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter, E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R., Waterson, R., and Wilson, R.	Public soybean EST project	Unpublished (1999)	R/Public Soybean EST project
	Contact: Shoemaker			

Email: [est@watson.wustl.edu](mailto:est@watson.wustl.edu)  
This clone is available through: Genome Systems, Inc. 4633 World Parkway Circle St. Louis Missouri 63134 For further information call: (800) 430-0030 or (314) 427-3222 FAX: (888) 919-3324 or (314) 427-3324 or contact: [clones@genomesystems.com](mailto:clones@genomesystems.com) or [infogenomesystems.com](http://infogenomesystems.com) web site: [www.genomesystems.com](http://www.genomesystems.com)  
Putative full length read

```

FEATURES
    source
        vector to vector length is 57.
        location/Qualifiers
            1..56
                /organism="Glycine max"
                /db_xref="taxon:3847"
                /clone="GENOME SYSTEMS CLONE ID: Gm-C1037-803"
                /clone_lid="Gm-C1037"
                /tissue_type="fully expanded leaves of greenhouse grown
                plants"
                /dev_stage="2 week old"
                /lab_host="DH10B"
                /note="vector: pSPORT1; site_1: NotI; site_2: SalI; This
                cDNA library was constructed from mRNA isolated from fully
                expanded leaves of greenhouse grown plants that were 2
                weeks old. The library was prepared using the Life
                Technologies psuperscript cDNA library construction kit.
                Complementary DNA was synthesized from mRNA using a
                poly(dT) sequence with a NotI restrictions site. SalI
                linkers adapters were ligated to the blunt-ended cDNA
                fragments followed by NotI digestion. The cDNA fragments
                were directionally cloned into the NotI-SalI restriction
                site of the pSPORT1 vector. The ligated cDNA fragments
                were transformed into E.coli Electro-Max DH10B host
                cells. This library was constructed in the laboratory of
                Dr. Lilia Vodkin by Anu Khanna at the University of
                Illinois at Urbana- Champaign. email: l-vodkin@uiuc.edu"
            15 a
                2 c
                11 g
                28 t

```

Query Match	2.0%	Score 20	DB 10	Length 56
Best Local Similarity	65.9%	Pred. NO. 1.1e+06		
Matches 29	Conservative 0	Mismatches 15	Indels 0	Gaps 0
Oy	846	tgttcagcctctaagatgaaatcgtgaacctcttcttactt	889	
Db	3	TTTTCAAGCTGCTATAGATGTTAAATGATATTTTGGTTTAACTT	46	

RESULT	15
AF149647	
LOCUS	AF149647 56 bp DNA
DEFINITION	AF149647 Human chromosome 18q21 from exon-trapping Homo sapiens genomic clone 5m10, DNA sequence.
ACCESSION	AF149647
VERSION	AF149647.1 GI:8485985
KEYWORDS	GSS.
SOURCE	human.
ORGANISM	Homo sapiens

REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
1 (bases 1 to 56)	Chen,H., Huo,Y., Patel,S., Zhu,X., Swift-Scanlan,T., Reeves,R.H., DePaulo,R. Jr., Ross,C.A. and McInnis,M.G.	Gene identification using exon amplification on human chromosome 18q21: implications for bipolar disorder	Mol. Psychiatry 5 (5), 502-509 (2000)	20485132
	Contact: Chen H	Psychiatry and Behavioral Sciences		
	Johns Hopkins University School of Medicine			
	600 N. Wolfe Street, Baltimore, MD 21287, USA			
	Email: hewei@link.welch.jhu.edu			
	Class: exon-trapped.			

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="18q21"
/clone="5m10"
/clone_lib="Human chromosome 18q21 from exon-trapping"
BASE COUNT      24 a      12 c      7 g      13 t
BRIGIN

```





alignment\_block:  
 US-09-439-311-2 x AAA86891/rev ..  
 Align seg 1/1 to reverse of: AAA86891 from: 1 to: 30

97 GlnAspGlyGlnSerLeuLysThrArgThr 106  
 |||||||  
 30 CACAGTGGACAAAGTTTAAAAACAAGAACT 1

seq\_name: /SID52/gcgdata/geneseq/geneseqn/NA2000.DAT:AAA86892

seq\_documentation\_block:  
 ID AAA86892 standard; DNA; 30 BP.  
 AC AAA86892;  
 XX  
 DT 15-JAN-2001 (first entry)  
 DE Probe to Campylobacter jejuni.  
 XX  
 KM Detection; nucleic acid hybrid; depolymerisation; analysis; SNP;  
 KM single nucleotide polymorphism; identification; viral load; probe;  
 KM genotyping; medical marker diagnostic; primer; target; mutation;  
 KM genetic disease; ss.  
 XX  
 OS Campylobacter jejuni.  
 XX  
 PN MO200049180-A1.  
 XX  
 PD 24-AUG-2000.  
 XX  
 PF 18-FEB-2000; 2000MO-US04242.  
 XX  
 PR 18-FEB-1999; 99US-0252436.  
 PR 21-JUL-1999; 99US-0358972.  
 PR 25-AUG-1999; 99US-0383316.  
 XX  
 PA (PROM-) PROMEGA CORP.  
 XX  
 PI Shultz JM, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;  
 PI Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;  
 XX  
 DR WPI: 2000-565377/52.  
 XX  
 PT Determining presence or absence of a predetermined endogenous nucleic  
 PT acid sequence by using an enzyme that depolymerizes the 3' end of an  
 PT oligonucleotide probe hybridized to a target sequence to release  
 PT identifier nucleotides -  
 XX  
 PS Example: Page 321: 389pp; English.  
 XX  
 CC The present invention describes a method (M1) for determining the  
 CC presence or absence of a predetermined endogenous nucleic acid target  
 CC sequence (ENAT). The method comprises hybridizing a probe having an  
 CC identifier nucleotide (IN) with ENAT which is treated with an enzyme  
 CC that depolymerizes the 3' end of hybridised NA to release the INs.  
 CC M1 is used for determining the number of known sequence repeats present  
 CC in a nucleic acid target sequence in a nucleic acid sample. The method  
 CC is also useful for determining whether a nucleic acid target sequence in  
 CC a sample is an allele from a homozygous or heterozygous locus. The  
 CC method is also useful for detection of mutations, translocations and  
 CC SNPs in nucleic acids (including those associated with genetic disease),  
 CC determination of viral load, species identification, sample  
 CC contamination, and analysis of forensic samples. AAA86791 to AAA87079  
 CC and AAA812817 represent sequence which are used in the exemplification of  
 CC the present invention.  
 CC N.B. There is a discrepancy between the SEQ ID NO: and sequences given  
 CC in the examples, and the SEQ ID NO: and sequences given in the sequence  
 CC listing from the present invention.  
 XX  
 SX Sequence 30 BP; 16 A; 4 C; 5 G; 5 T; 0 other:

alignment\_scores:  
 Quality: 50.00 Length: 10  
 Ratio: 5.000 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:  
 US-09-439-311-2 x AAA86892 ..  
 Align seg 1/1 to: AAA86892 from: 1 to: 30

97 GlnAspGlyGlnSerLeuLysThrArgThr 106  
 |||||||  
 1 CACAGTGGACAAAGTTTAAAAACAAGAACT 30

seq\_name: /SID52/gcgdata/geneseq/geneseqn/NA2000.DAT:AAA93188

seq\_documentation\_block:  
 ID AAA93188 standard; DNA; 30 BP.  
 AC AAA93188;  
 XX  
 DT 11-JAN-2001 (first entry)  
 DE Campylobacter jejuni interrogation probe 11451.  
 XX  
 KM Campylobacter jejuni; nucleic acid detection; genomic typing;  
 KM mutation detection; viral load determination; species identification;  
 KM forensic analysis; probe; ss.  
 XX  
 OS Campylobacter jejuni.  
 XX  
 PN MO200049179-A1.  
 XX  
 PD 24-AUG-2000.  
 XX  
 PF 18-FEB-2000; 2000MO-US04176.  
 XX  
 PR 18-FEB-1999; 99US-0252436.  
 PR 21-JUL-1999; 99US-0358972.  
 PR 27-SEP-1999; 99US-0406147.  
 XX  
 PA (PROM-) PROMEGA CORP.  
 XX  
 PI Shultz JM, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;  
 PI Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;  
 XX  
 DR WPI: 2000-549282/50.  
 XX  
 PT Detecting the presence of predetermined exogenous nucleic acid target  
 PT sequence useful for e.g. genotyping, comprises depolymerizing the 3'  
 PT end of an oligonucleotide probe hybridized to a nucleic acid target  
 PT sequence -  
 XX  
 PS Claim 47: Page 187: 230pp; English.  
 XX  
 CC The present sequence is an interrogation probe which was used to detect a  
 CC segment of the genome of Campylobacter jejuni. This was performed as part  
 CC of a method for determining the presence of a known exogenous nucleic  
 CC acid target sequence in a nucleic acid sample. The method comprises  
 CC admixing a treated sample with a depolymerising enzyme which releases one  
 CC or more nucleotides from the 3'-end of a hybridised nucleic acid probe.  
 CC The method is used for assaying nucleic acids for a particular native or  
 CC mutant sequence, and for genomic typing. It is useful for detecting  
 CC mutations, translocations, and single nucleotide polymorphisms,  
 CC determination of viral load, species identification, detection of sample  
 CC contamination, and analysis of forensic samples. Compared with previous  
 CC methods of detecting nucleic acid hybrids, the new method has higher  
 CC sensitivity without the need for radiochemicals or electrophoresis. It is  
 CC quantitative, highly reproducible and can be automated. The method can  
 CC reliably detect as few as 10 copies of a virus in a sample, and is  
 CC capable of providing multiple analyses in a single assay (multiplex  
 CC assay).

XX  
SQ Sequence 30 BP; 5 A; 5 C; 4 G; 16 T; 0 other:

alignment\_scores:  
Quality: 50.00 Length: 10  
Ratio: 5.000 Gaps: 0  
Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:

US-09-439-311-2 x AAA93188/rev ..

Align seg 1/1 to reverse of: AAA93188 from: 1 to: 30

97 GlnApglGlnSerLeuLysThrArgThr 106  
|||||  
30 CAAGATGACAAAGTTAAAAACAAGAACT 1

seq\_name: /SID22/gcgdata/geneseq/geneseqn/NA2000.DAT:AAA93190

seq\_documentation\_block:

ID AAA93190 standard; DNA: 30 BP.

XX AAA93190;

XX 11-JAN-2001 (first entry)

XX Campylobacter jejuni interrogation probe 11450.

XX Campylobacter jejuni; nucleic acid detection; genomic typing;

KW mutation detection; viral load determination; species identification;

XX forensic analysis; probe; ss.

XX Campylobacter jejuni.

XX WO200049179-A1.

XX 24-AUG-2000.

XX 18-FEB-2000; 2000MO-US04176.

XX 18-FEB-1999; 99US-0252436.

XX 21-JUL-1999; 99US-0358972.

XX 27-SEP-1999; 99US-0406147.

XX (PROM-) PROMEGA CORP.

XX Shultz JM, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;

XX Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

XX WPI: 2000-549282/50.

XX Claim 47; Page 187; 230pp; English.

XX The present sequence is an interrogation probe which was used to detect a  
CC segment of the genome of Campylobacter jejuni. This was performed as part  
CC of a method for determining the presence of a known exogenous nucleic  
CC acid target sequence in a nucleic acid sample. The method comprises  
CC admitting a treated sample with a depolymerising enzyme which releases one  
CC or more nucleotides from the 3'-end of a hybridised nucleic acid probe.  
CC The method is used for assaying nucleic acids for a particular native or  
CC mutant sequence, and for genomic typing. It is useful for detecting  
CC mutations, translocations, and single nucleotide polymorphisms.  
CC determination of viral load, species identification, detection of sample  
CC contamination, and analysis of forensic samples. Compared with previous  
CC methods of detecting nucleic acid hybrids, the new method has higher  
CC sensitivity without the need for radiochemicals or electrophoresis. It is  
CC quantitative, highly reproducible and can be automated. The method can

CC reliably detect as few as 10 copies of a virus in a sample, and is  
CC capable of providing multiple analyses in a single assay (multiplex  
CC assay).

XX  
SQ Sequence 30 BP; 16 A; 4 C; 5 G; 5 T; 0 other:

alignment\_scores:  
Quality: 50.00 Length: 10  
Ratio: 5.000 Gaps: 0  
Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:

US-09-439-311-2 x AAA93190 ..

Align seg 1/1 to: AAA93190 from: 1 to: 30

97 GlnApglGlnSerLeuLysThrArgThr 106  
|||||  
1 CAAGATGACAAAGTTAAAAACAAGAACT 30

seq\_name: /SID22/gcgdata/geneseq/geneseqn/NA1998.DAT:AAV23196

seq\_documentation\_block:

ID AAV23196 standard; DNA: 59 BP.

XX AAV23196;

XX 28-JUL-1998 (first entry)

XX Lactococcus lactis constitutional promoter Cp29.

KW Lactococcus lactis; constitutional promoter; optimise; spacer;

XX artificial promoter library; gene expression; ds.

XX Lactococcus lactis.

XX Synthetic.

XX WO9807846-A1.

XX 26-FEB-1998.

XX 25-AUG-1997; 97WO-DK00342.

XX 23-AUG-1996; 96DK-0000886.

XX (JENSEN) JENSEN P R.

XX Hammer K, Jensen PR;

XX WPI: 1998-179062/16.

XX Claim 28; Page 52; 89pp; English.

XX This is a Lactococcus lactis constitutional promoter sequence used in the  
CC construction of an artificial promoter library of the invention. The  
CC artificial promoter library for a selected organism or group of organisms  
CC comprise a mixture of double-stranded DNA fragments, the sense strands of  
CC which comprise at least half of two consensus sequences of efficient  
CC promoters from the organism or group of organisms and surrounding or  
CC intermediate nucleotide sequences (spacers) of variable length in which  
CC at least 7 nucleotides are selected randomly, with the proviso that  
CC previously known promoter sequences and promoter sequences isolated from  
CC natural sources are not included. This promoter library can be used in a

```

CC  converters or endoproteases that exhibit testis specificity.
CC  Antagonists, including antibodies, are useful for inhibiting or
CC  eliminating the function of ZSIC-11. It is possible that ZSIC-11 and
CC  its antagonists will be useful as fertility inducing therapeutics.
CC  Sequences AAX34800-21 represent PCR primers for amplifying the ZSIC-11
CC  DNA.
XX
SO  Sequence 51 BP; 17 A; 5 C; 19 G; 10 T; 0 other;
CC
Alignment_scores:
      Quality: 43.00      Length: 16
      Ratio: 3.583      Gaps: 0
Percent Similarity: 75.000      Percent Identity: 50.000
CC
Alignment_block:
US-09-439-311-2 x AAX34813 ..
CC
Align seg 1/1 to: AAX34813 from: 1 to: 51
CC
253 GlyValValIleGlyValAspPyrSerAspGlyAspGluAsnGly 268
||||| :||| |||||:||||| |||:|||||
1 GGTGTAACTCTGGACACAGAGATTACAGACGATGTCACAAAGGT 48
seq_name: /SIDIS2/gcgdata/geneseq/geneseqn/NA1999.DAT.AAX19519
seq_documentation_block:
ID AAX19519 standard; DNA; 51 BP.
XX
AC AAX19519;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human lipocalin homologue zlipol PCR primer ZC13,735.
XX
KW Human; lipocalin; testis; mammary gland; breast tumour; zlipol;
KW breast cancer; emphysema; skin disease; reproduction; anti-inflammatory;
KW antimicrobial; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN W03907740-A2.
XX
PD 18-FEB-1999.
XX
PF 06-AUG-1998; 98MO-US16425.
XX
PR 06-AUG-1997; 97US-0054867.
XX
PA (ZYMO ) ZYMOGENETICS INC.
XX
PI Conklin DC;
XX
XR WPI; 1999-167367/14.
XX
PT New lipocalin homologue designated zlipol - whose expression is
PT restricted to testis and mammary gland tissues, particularly breast
PT tumour tissue, used to, e.g. predict tumour aggressiveness.
XX
PS
XX
Example 5; Page 89; 94pp; English.

```



CC system to transport and/or stabilise small lipophilic molecules, e.g. to  
CC protect from gut pH and digestive enzymes. They can also be used to bind  
CC small fatty acids in blood or tissues to modulate their biological  
CC function, e.g. to transport retinoids or steroids to receptors, in  
CC particular as therapy for breast cancer, emphysema and diseases of the  
CC skin. They may also play an important role in reproduction. Other uses  
CC include anti-inflammatory responses, and antimicrobial activities.  
CC Zilipol nucleic acid sequences may be used for gene therapy to increase  
CC or inhibit zilipol activity, to derive probes and primers, to derive  
CC antisense sequences, and to detect genetic abnormalities.  
XX  
SQ Sequence 51 BP; 17 A; 5 C; 19 G; 10 T; 0 other;

alignment\_scores:  
Quality: 43.00 Length: 16  
Ratio: 3.583 Gaps: 0  
Percent Similarity: 75.000 Percent Identity: 50.000

alignment\_block:  
US-09-439-311-2 x AAX19519 ..

Align seg 1/1 to: AAX19519 from: 1 to: 51

253 G1YVAlVal11eG1yLysVAlAsPTySerAspG1yAspG1uAsnG1y 268  
||||| :||| |||||:||||| |||||:|||||  
1 GGTGAACCTTGACACAGACAGATTACACAGACGATGATGACACAGCT 48

seq\_name: /SIDS2/gcgdata/geneseq/geneseq/NA1998.DAT:AAV00234

seq\_documentation\_block:  
ID AAV00234 standard; DNA: 50 BP.  
XX  
AC AAV00234:  
XX  
DT 08-JUN-1998 (first entry)  
XX  
DE Tick vasactive amine binding protein FS-HBPI reverse PCR primer.  
XX  
KW Female-specific vasactive amine binding protein 1; FS-HCPI;  
KW histamine; serotonin; assay; antihistamine; anti-inflammatory;  
KW insect bite; snake bite; scorpion bite; dermatitis; vaccine;  
KW transgenic animal; tick; PCR; primer; ss.  
XX  
OS Synthetic.  
OS Rhipicephalus appendiculatus.  
XX  
PN WO9744451-A2.  
XX  
PD 27-NOV-1997.  
XX  
PF 19-MAY-1997; 97WO-GB01372.  
XX  
PR 18-APR-1997; 97GB-0007844.  
PR 18-MAY-1996; 96GB-0010484.  
XX  
PA (OXFO-) OXFORD VACS LTD.  
XX  
PI Nuttall PA, Paesen GC;  
XX  
DR WPI: 1998-018506/02.  
XX  
PT New vasactive amine binding proteins and related nucleic acid,  
PT vectors - transformed cells and transgenic animals, used for  
PT assaying or removing histamine and as antihistamine or  
PT anti-inflammatory agents  
XX  
PS Example 3; Page 20; 44pp; English.  
XX  
CC This reverse primer was used with a forward primer (see AAV00233)  
CC to amplify the coding region (see AAV00227) of Rhipicephalus  
CC appendiculatus female-specific histamine binding protein 1  
CC (FS-HBPI) (see AAW37446), a novel vasactive amine binding protein

CC (VABP). The primers were designed so that a SacI site was added  
CC upstream of the start codon, while the stop codon was replaced by  
CC a BamHI site, followed by 6 histidine codons and an SpeI site  
CC comprising a T66 stop codon. The PCR product was ligated into  
CC transfect vector pAC1291, generating plasmid pAC129.1-FS1.HIS.  
CC FS-HBPI was expressed as a histidine-tagged protein in Spodoptera  
CC frugiperda Sf21 ovarian cells using a baculovirus expression system.  
CC VABPs can be used to assay or remove histamine, as an antihistamine  
CC or anti-inflammatory agent, and in vaccines.  
XX  
SQ Sequence 50 BP; 11 A; 8 C; 14 G; 17 T; 0 other;

alignment\_scores:  
Quality: 41.00 Length: 10  
Ratio: 4.100 Gaps: 0  
Percent Similarity: 100.000 Percent Identity: 70.000

alignment\_block:  
US-09-439-311-2 x AAV00234 ..

Align seg 1/1 to: AAV00234 from: 1 to: 50

262 SerAspG1yAspG1uAsnG1ySerLeu1le 271  
||||| |||||:||||| |||||:|||||  
7 AGTGATGCTGATGATGATGATGATGATGATGATGATGATGATGATG 36

seq\_name: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT:AAZ96924

seq\_documentation\_block:  
ID AAZ96924 standard; DNA: 59 BP.  
XX  
AC AAZ96924:  
XX  
DT 14-APR-2000 (first entry)  
XX  
DE S. cerevisiae gene deletion cassette constructing primer YMR290C-S1.  
XX  
KW Antimycotic; mycosis; immunodepression; AIDS; diabetes; fungicide;  
KW mycel; gene deletion; PCR primer; ss.  
XX  
OS Saccharomyces cerevisiae.  
XX  
PN WO9955907-A2.  
XX  
PD 04-NOV-1999.  
XX  
PF 22-APR-1999; 99WO-EP02722.  
XX  
PR 24-APR-1998; 98EP-0401007.  
PR 11-SEP-1998; 98EP-0402254.  
XX  
PA (HMRI ) HOECHST MARION ROUSSEL.  
XX  
PI Diu-Hercend A, Entian K, Koetter P;  
XX  
DR WPI: 2000-105527/09.  
XX  
PT Identifying antimycotic substances useful for drug preparation and  
PT treatment of mycosis -  
XX  
PS Examples; Page 71; 86pp; English.  
XX  
CC The invention provides a method of screening for antimycotic substances  
CC using essential genes from mycelles or a functionally similar mycelle  
CC gene or the corresponding encoded protein as target. The essential gene  
CC useful for screening antimycotic substances is selected from the  
CC following genes: YML114C, YLR186W, YLR215C, YLR222C, YLR243W, YLR272C,  
CC YLR275W, YLR276C, YLR317W, YLR359W, YLR373C, YLR424W, YLR437C, YLR440C,  
CC YML023C, YML049C, YML077W, YML127W, YMR032W, YMR093W, YMR131C,  
CC YMR185W, YMR213W, YMR218C, YMR281W, YMR288W, YMR290C, YMR211W,  
CC YMR049C, YMR134W, YDR196C, YDR299W, YDR365C, YDR407C, YDR416W,  
CC YDR449C, YDR472W, YDR499W, YDR141C, YDR324C, YDR325W, YDR398W, YDR246W,

XX The sequences given in AAT00202-25 and AAT00227-57 represent two groups  
CC of ligands to thrombin. These sequences were isolated using the single  
CC stranded DNA molecules given in AAT00201 and AAT00226 which comprise a  
CC 30N and a 60N variable region, respectively. These ligands were  
CC isolated using systematic evolution of ligands by exponential enrichment  
CC (SELEX). The selection was conducted in a buffer solution at 37 deg. C.  
CC After 12 rounds of selection, no additional improvement in binding was  
CC seen. By studying regions of homology between the isolated ligands, a  
CC truncated ligand of 38 nucleotides (see AA098403-04) was identified which  
CC retains high affinity binding and inhibits clotting. These ligands are  
CC inhibitors of thrombin and are therefore useful in treating thrombin  
CC mediated conditions and in studying the structure and binding of  
CC thrombin.  
XX  
XX  
SQ Sequence 60 BP; 10 A; 11 C; 29 G; 10 T; 0 other;

[illegible]

Align seg 1/1 to: AAT0025

Align seg 1/1 to: AAT00254 from: 1 to: 60

```

204 ThSvTaGtGThrclyLeuGlValaLeuAglGluGluIleAsnArgAs 220
    |||::: |||:::||||| ||||||||::: ::::: ::
4   ACCGCGGAGGAGCGCTAGAGTGTGGAGGCGTTGGCCCGATGTGTGAGGCACGGA 53
220 nAlaAsp 222

```

220 nAlaasp 222

54 CTCGGAT 60

seq\_name: /SIDS2/gcgcdata/geneseq/geneseqn/NA2001.DAT :AAF70806

ID AAF70806 standard; DNA; 60 BP.

AC AAF70806;

DT 20-APR-2001 (first entry)

Thrombin high affinity ligand #53.

KW Ligand; basic fibroblast growth factor; bFGF; gene therapy; vascular;

XX  
XX

2X  
2  
2  
2  
2  
2  
2  
2  
2  
2

XX  
XX  
TAN-2001

XX 05 AUG 1965 060743Z  
BT

XX	11 - TUN-1000.	00115-0E36430
DE		

PR	10-JUN-1991;	91US-0714131.
PR	06-NOV-1993;	93US-0672323

PR	10-FEB-1994;	94US-0195005.
PR	28-MAR-1994;	04US-0210013

XX  
XX  
DA (NYSC-) NEWCASTL BUNDM TNG

[illegible]

XX WPT. 2001-1E9E93/1E

XX	Novel nucleic acid ligands to basic fibroblast growth factor that are
PT	useful as inhibitors of basic fibroblast growth factors and 2'-amino
PT	modified RNA ligands, exhibit increased in vivo stability -

```

XX PS Example 19; Column 59-60: 153pp; English.
CC CC The present invention relates to a purified and isolated non-naturally
XX CC occurring DNA ligands to basic fibroblast growth factor (bFGF).
CC CC The ligands are useful as part of gene therapy treatments and
CC CC for diagnosing pathogenesis of vascular diseases including
CC CC intillation and progression of atherosclerosis, acute coronary
CC CC syndromes, vein graft disease and restenosis following coronary
CC CC angioplasty. The ligands have improved stability in vivo.
XX CC
SQ Sequence 60 BP; 10 A; 11 C; 29 G; 10 T; 0 other;

alignment_scores:
    Quality: 40.00      Length: 19
    Ratio: 2.667       Gaps: 0
Percent Similarity: 78.947 Percent Identity: 42.105

alignment_block:
US-09-439-311-2 x AAF70806 ..

Align seg 1/1 to: AAF70806 from: 1 to: 60

204 ThisSeValGlyThrGlyLeuGlyAlaLeuAlaGluGluIleAsnArgAs 220
      |||::: |||:::||||||| |||:::|||||::: ::::: ::
4 ACCGGCGAGGGCGCTAGAGGTTGAGAGCGTGTGCCGATGCTGAGCGACGGA 53
220 nalaasp 222
      :::::|||
54 CTCGCAT 60

seq_name: /SID52/gcgcdata/geneseq/geneseqn/NA2001.DAT:AAI30690
seq_documentation_block:
ID AAI30690 standard; DNA; 31 BP.
XX
XX AAI30690:
XX
XX 18-OCT-2001 (first entry)
XX
XX Human single nucleotide polymorphism (SNP) ATM 2.
XX
XX Human: resequence; genotype: disease; forensic; paternity testing;
XX single nucleotide polymorphism; SNP; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH replace(16.C)
FT Variation /tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
XX NC0200166800-A2.
XX
XX 13-SEP-2001.
XX
XX 07-MAR-2001: 2001MO-US07268.
XX
XX 07-MAR-2000: 2000US-0187510.
XX
XX 22-MAY-2000: 2000US-0206129.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX
XX MPI; 2001-522952/57.
XX
XX Nucleic acid molecules from the human genome which include polymorphic
XX sites, useful in methods for predicting the presence, absence or
XX severity of a particular phenotype or disorder (e.g. diabetes)
XX associated with a particular genotype -
XX

```

```

PS Claim 1, Page 101, 145pp: English.
XX The invention relates to the identification of nucleic acid molecules
CC (AAI29513-AAI1314) from the human genome which include polymorphic sites
CC which can predispose individuals to disease. Various genes from a number
CC of individuals were resequenced and single nucleotide polymorphisms
CC (SNPs) in these genes discovered. The method is useful for predicting the
CC presence, absence or severity of a particular phenotype or disorder (e.g.
CC diabetes) associated with a particular genotype. The nucleic acids
CC containing the polymorphic sites may be useful in forensics and paternity
CC testing.
XX
SQ Sequence 31 BP; 12 A; 4 C; 7 G; 8 T; 0 other;
XX
alignment_scores:
    Quality: 39.00      Length: 9
    Ratio: 4.333      Gaps: 0
Percent Similarity: 100.000      Percent Identity: 77.778
XX
alignment_block:
US-09-439-311-2 x AAI30690 ..
XX
Align seg 1/1 to: AAI30690 from: 1 to: 31
XX
139 ThrAsngInglupheGlnIleGlySer 147
|||||:|||||:|||||F||||
5 ACAATGAGCAATTCACGAAATGTGTTCC 31
XX
seq_name: /SIDS2/gcgdata/geneseq/geneseqn/AAI1998.DAT:AAV56429
XX
seq_documentation_block:
ID AAV56429 standard; DNA; 47 BP.
XX
AC AAV56429;
XX
DT 20-NOV-1998 (first entry)
XX
DE Human ICAM-R cDNA primer #27.
XX
Intercellular adhesion molecule; ICAM-R; human; modulator; 14.3.3 family;
KW HSI-beta; tubulin; inhibitor; stimulator; effector; immune response;
KW inflammation; disorder; T cell activation; macrophage; Crohn's disease;
KW adult respiratory distress syndrome; stroke; multiple sclerosis; asthma;
KW rheumatoid arthritis; tumour growth; human immune deficiency virus;
KW infection; diabetes; graft vs. host disease; passive immunisation;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5773218-A.
XX
30-JUN-1998.
XX
07-JUN-1995; 95US-0482882.
XX
05-AUG-1994; 94US-0286754.
XX
27-JAN-1992; 92US-0827689.
XX
26-MAY-1992; 92US-0889724.
XX
05-JUN-1992; 92US-0894061.
XX
22-JAN-1993; 93US-0009266.
XX
26-JAN-1993; 93MO-US00787.
XX
05-AUG-1993; 93US-0102852.
XX
07-JUN-1995; 95US-0482882.
XX
(ICOS-) ICOS CORP.
XX
Gallatin WM, Vazeux R;
XX
WPI, 1998-386989/33.
XX
Identifying compounds that modulate interaction of intercellular

```

PT adhesion molecule R - with ligands HSI-beta and tubulin using  
PT two-hybrid assay, useful for treating inflammation, T cell  
XX activation etc.  
XX  
PS Example 13; Column 135-136; 108pp; English.  
XX  
CC AAV56429-V56434 are primers used in the isolation of a novel human  
CC intercellular adhesion molecule, ICAM-R. This sequence is used in a  
CC method which investigates modulators of the interaction between ICAM-R  
CC and the 14.3.3 family member HSI-beta and tubulin. An anti-ICAM-R  
CC antibody optionally coupled to toxin or radionuclide, or an ICAM-R  
CC peptide can block, inhibit or stimulate ligand/receptor interactions  
CC involving ICAM-R, particularly its effector functions involved in  
CC (non)specific immune responses. ICAM-R related agents may be used to  
CC treat or monitor inflammation, disorders involving T cell activation or  
CC macrophages, e.g. adult respiratory distress syndrome, stroke, Crohn's  
CC disease, multiple sclerosis, rheumatoid arthritis, asthma, tumour  
CC growth, human immune deficiency virus infection, diabetes, graft vs. host  
CC disease and many others. Antibodies may also be used for passive  
CC immunisation, for purifying, detecting or quantifying ICAM-R and for  
CC identifying ICAM-R expressing cells.  
XX  
SQ Sequence 47 BP; 9 A; 21 C; 7 G; 10 T; 0 other:  
  
alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667  
  
alignment\_block:  
US-09-439-311-2 x AAV56429/rev ..  
  
Align seg 1/1 to reverse of: AAV56429 from: 1 to: 47  
  
169 ArgpHeGIuThnGlySerGlnSerPheSerSergly 180  
||||:||||||||| |||:|||||  
44 AGGATGGAGACTGGCTCAGCAGATTGGGAGTGA 9  
  
seq\_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1999.DAT:AAV21884  
  
seq\_documentation\_block:  
ID AAV21884 standard; DNA: 47 BP.  
XX  
AC AAV21884;  
XX  
DT 14-MAY-1999 (first entry)  
XX  
DE Primer for antibody against ICAM-R.  
XX  
KW ICAM; immunoglobulin-like loop; intercellular adhesion molecule receptor;  
KW alpha d/CD18; antibody; immunisation; inflammatory response; asthma;  
KW tumour growth; viral infection; therapy; primer; ss.  
XX  
OS Synthetic.  
OS Mus sp.  
PN US5880268-A.  
XX  
PD 09-MAR-1999.  
XX  
PF 07-JUN-1995; 95US-0483932.  
XX  
PR 05-AUG-1994; 94US-0286754.  
PR 27-JAN-1992; 92US-0827689.  
PR 26-MAY-1992; 92US-0889724.  
PR 05-JUN-1992; 92US-0894061.  
PR 22-JAN-1993; 93US-0009266.  
PR 26-JAN-1993; 93WO-US00787.  
PR 05-AUG-1993; 93US-0102852.  
PR 07-JUN-1995; 95US-0483932.  
XX  
PA (ICOS-) ICOS CORP.

XX  
PI Gallatin WM, Vazeux R;  
XX  
DR WPI; 1999-204041/17.  
XX  
XX  
PT New intercellular adhesion molecule receptor (ICAM-R) specific  
PT antibodies - useful for modulating ligand/receptor binding and  
PT biological activities involving ICAM-R, especially those of the  
XX specific and non-specific immune systems  
XX  
PS Example 13; Column 41; 108pp; English.  
XX  
CC This sequence is a primer for DNA encoding an antibody specific for  
CC ICAM-R. The invention relates to antibodies (Ab) which bind specifically  
CC to the intercellular adhesion molecule receptor (ICAM-R), inhibiting the  
CC interaction between ICAM-R and alpha d/CD18. Abs with specific ICAM-R  
CC binding are useful in compositions for immunisation, and for purifying  
CC ICAM-R polypeptides and identifying cells expressing ICAM-R on their cell  
CC surface, modulating ligand/receptor binding and biological activities  
CC involving ICAM-R, especially inflammatory responses of the specific  
CC immune system, the non-specific immune system, monitoring and treating  
CC asthma, tumour growth, and/or metastasis, and viral infection (e.g. HIV  
CC infection). In particular diseases involving an essential T cell  
CC activation (e.g. asthma, psoriasis, diabetes, graft vs. host disease,  
CC tissue transplant rejection, and multiple sclerosis) may be treated with  
CC anti-ICAM-R antibodies. The Abs specifically bind to and identify ICAM-R  
CC binding.  
XX  
SQ Sequence 47 BP; 9 A; 21 C; 7 G; 10 T; 0 other:  
  
alignment\_scores:  
Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667  
  
alignment\_block:  
US-09-439-311-2 x AAV21884/rev ..  
  
Align seg 1/1 to reverse of: AAV21884 from: 1 to: 47  
  
169 ArgpHeGIuThnGlySerGlnSerPheSerSergly 180  
||||:||||||||| |||:|||||  
44 AGGATGGAGACTGGCTCAGCAGATTGGGAGTGA 9  
  
seq\_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1999.DAT:AAV69197  
  
seq\_documentation\_block:  
ID AAV69197 standard; DNA: 47 BP.  
XX  
AC AAV69197;  
XX  
DT 17-FEB-1999 (first entry)  
XX  
DE Humanised ICR-1.1 antibody vK region DNA mutating oligo 110.  
XX  
KW Intercellular adhesion molecule polypeptide; ICAM-R; humanised; ICR 1.1;  
KW ICR 8.1; monoclonal antibody; therapeutic; inflammatory; asthma; tumour;  
KW graft-versus-host disease; viral infection; toxin; radionuclide;  
KW neovascularisation site; mutagenic; PCR primer; ss.  
XX  
OS Synthetic.  
OS Mus sp.  
PN US5837822-A.  
XX  
PD 17-NOV-1998.  
XX  
PF 07-JUN-1995; 95US-0487113.  
XX  
PR 07-JUN-1995; 95US-0487113.  
PR 27-JAN-1992; 92US-0827689.

PR 26-MAY-1992: 92US-0889724.  
 PR 05-JUN-1992: 92US-0894061.  
 PR 22-JAN-1993: 93US-0009266.  
 PR 26-JAN-1993: 93WO-US00787.  
 PR 05-AUG-1993: 93US-0102852.

XX  
 XX  
 PA (ICOS-) ICOS CORP.

PI Gallatin NM, Vazeux R;

DR WPI: 1999-023535/02.

XX  
 XX  
 PR Humanised antibodies specific for intercellular adhesion molecule  
 PT polypeptide - useful for therapeutic or diagnostic purposes

XX  
 PS Example 13: Column 42: 116pp: English.

XX  
 CC The invention relates to humanised ICR 1.1 and ICR 8.1 antibodies  
 CC targeted to the human intercellular adhesion molecule polypeptide  
 CC (ICAM-R) polypeptide. Antibodies specific for ICAM-R are potentially  
 CC useful as therapeutic compounds, for treating e.g. immune-mediated  
 CC inflammatory conditions (e.g. graft-versus-host disease), asthma,  
 CC tumours or viral infections. Monoclonal antibodies specific for ICAM-R,  
 CC or their conjugates formed with e.g. toxins or radionuclides are useful  
 CC for therapeutically targeting or detecting neovascularisation sites.  
 CC PCR mutagenic oligos AAV69197 and AAV69198 are used in the construction  
 CC of the V<sub>K</sub> region of the humanised antibody ICR-1.1.  
 XX  
 SO Sequence 47 BP: 9 A; 21 C; 7 G; 10 T; 0 other:

# alignment\_scores:

Quality:	39.00	Length:	12
Ratio:	3.900	Gaps:	0
Percent Similarity:	83.333	Percent Identity:	66.667

# alignment\_block:

US-09-439-311-2 x AAV69197/rev ..

Align seg 1/1 to reverse of: AAV69197 from: 1 to: 47

169 ArgPheGluThrGlySerGlnSerPheSerSercly 180  
 |||:::||||||| |||:::|||||  
 44 AGGATGGGAGCTGGCTCAGCAGCATTTGGAGTGA 9



OM of: US-09-439-311-2 to: EST:\* out\_format : pfs

Date: Apr 17, 2002 2:43 AM

About: Results were produced by the GenCore software, version 4.5,  
Copyright (c) 1993-2000 Compugen Ltd.

#### Command line parameters:

```
-MODEL=frame+pen.model -DEV=rlp
-O/cgcn2.1/USPTO_spool/US09433311/runat_16042002_134010_11677/app_query.fasta_1.395
-DB=EST -OFMT=fastap -SUFFIX=est -GAPOP=12.000 -GAPEXT=4.000
-MINMATCH=0.100 -LOOPEL=0.000 -LOOPEXT=0.000 -OGAPOP=4.500
-OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -FGAPOP=6.000
-FCAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500 -DEL0P=6.000
-DELXT=7.000 -START=1 -MATRIX=bloms62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pis -NORM=ext -MINLEN=0 -MAXLEN=60
-USER=US09433311@CGCN_1.3691 -NCPU=6 -ICPU=3 -LONGLOG -NO_XLPHY
-WAIT -THREADS=1
```

#### Search information block:

```
Query: US-09-439-311-2
Query length: 333
Database: EST:*
Database sequences: 11351937
Database length: 1077921985
Search time (sec): 1467.110000
```

#### score\_list:

Sequence	Strd	Orig	ZScore	Escore	Len	Documentation
gb_estl:AU104260	+	48.00	103.91	1.3e+04	50	AU104260 AU104260 Sugano Homo sa
gb_gss:B04096	+	45.00	96.72	1.2e+04	60	B04096 CSRL-25g1-u CSRL flow sor
gb_gss:AZ65973	+	33.00	88.52	9.0e+04	44	AZ65973 IM0283E04R Mouse 10kb F
gb_estl:AU107968	+	33.00	87.43	1.0e+05	50	AU107968 AU107968 Sugano Homo sa
gb_estl:W20078	+	33.00	87.07	1.1e+05	52	W20078 zb40e03.r1 Soares_parity
gb_gss:AZ231603	+	33.00	86.21	1.2e+05	57	AZ231603 1006030F10.x1 1006 - Re
gb_gss:AZ298589	+	38.50	85.80	1.3e+05	54	AZ298589 2M0285D08R Mouse 10kb F
gb_estl:AU106648	+	38.00	85.60	1.3e+05	50	AU106648 AU106648 Sugano Homo sa
gb_estl:C20861	+	38.00	84.55	1.5e+05	56	C20861 HUMG50004926 Human adult
gb_gss:AZ654882	+	38.00	84.38	1.5e+05	57	AZ654882 IM0529N22F Mouse 10kb F
gb_estl:AA628048	+	37.00	83.90	1.6e+05	60	AA628048 ng62f05.s1 NCI_CGAP_OV4
gb_gss:AZ429658	+	37.00	83.93	1.0e+05	33	AZ429658 IM0213A18R Mouse 10kb F
gb_estl:AU1595782	+	37.00	83.96	1.6e+05	49	AU1595782 u169c12.x1 Sugano mouse
gb_estl:AU102738	+	37.00	83.77	1.7e+05	50	AU102738 AU102738 Sugano Homo sa
gb_gss:CN504000	+	37.00	83.53	1.8e+05	53	AL269171 Tetraodon nigroviridis
gb_estl:AA664752	+	37.00	82.55	2.0e+05	57	AA664752 nu65c03.s1 NCI_CGAP_A1V
gb_estl:AU1320166	+	37.00	82.39	2.0e+05	58	AU1320166 c1e11m.f1 Neurospora c
gb_gss:AZ2996603	+	36.50	81.47	2.3e+05	58	AZ2996603 2M0282P18R Mouse 10kb F
gb_estl:AZ1552735	+	36.00	83.78	1.7e+05	41	AZ615427 IM0444G18R Mouse 10kb F
gb_estl:AZ1542735	+	36.00	82.71	1.9e+05	46	AZ152735 fb61e01.x1 Zebrafish wa
gb_gss:AZ238471	+	36.00	82.32	2.0e+05	48	AZ238471 IM0052F16F Mouse 10kb F
gb_estl:AU105900	+	36.00	81.94	2.1e+05	50	AU105900 AU105900 Sugano Homo sa
gb_estl:AU1905591	+	36.00	81.94	2.2e+05	51	AU1905591 CM-BR094-050299-117 BRC
gb_gss:AZ402345	+	36.00	81.75	2.2e+05	51	AZ402345 IM0169B10R Mouse 10kb F
gb_estl:BF043282	+	36.00	81.57	2.2e+05	52	BF043282 h48h12.y1 NCI_CGAP_OV3
gb_estl:AA673303	+	36.00	81.05	2.4e+05	55	AA673303 v069f08.r1 Barstead mol
gb_estl:AA711965	+	36.00	81.05	2.4e+05	55	AA711965 v29c06.x1 Zebrafish wa
gb_estl:AA444123	+	36.00	81.05	2.4e+05	55	AA444123 fb26b06.x1 Zebrafish wa
gb_estl:AU1831222	+	36.00	81.05	2.4e+05	59	AU1831222 w182d10.x1 NCI_CGAP_LY
gb_gss:AZ12625	+	35.50	79.48	2.9e+05	55	AZ12625 IM0168L07F Mouse 10kb F
gb_estl:AU163369	+	35.00	81.51	2.2e+05	43	AU163369 th62d06.x1 NCI_CGAP_OV2
gb_estl:W53889	+	35.00	81.51	2.2e+05	43	W53889 md03h05.r1 Soares mouse e
gb_estl:AU007710	+	35.00	80.29	2.6e+05	49	AU007710 AU007710 Schizosaccharc
gb_estl:AA400193	+	35.00	80.29	2.6e+05	49	AA400193 zu64e08.s1 Soares_testi
gb_estl:AU106926	+	35.00	80.11	2.7e+05	50	AU106926 AU106926 Sugano Homo sa
gb_estl:AU1653027	+	35.00	79.74	2.8e+05	52	AU1653027 tv36h11.x1 NCI_CGAP_G6
gb_estl:AA449400	+	35.00	79.74	2.8e+05	52	AA449400 zx04f01.r1 Soares_tot
gb_estl:BB65043	+	35.00	78.92	3.0e+05	55	BB65043 sad50f03.y2 Gm-cl075 G1
gb_estl:BG095988	+	35.00	78.89	3.1e+05	57	BG095988 nag54e01.x1 NCI_CGAP_Cd

seq\_name: gb\_estl:AU104260

seq\_documentation\_block:

LOCUS AU104260 50 bp mRNA EST 05-APR-2001

DEFINITION AU104260 Sugano Homo sapiens CDNA library Homo sapiens CDNA clone

ACCESSION AU104260

VERSION AU104260.1 GI:13553781

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 50)

Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Hata ,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,T., Morishita,S., Okubo ,K., Suyama,A. and Sugano,S.

Fine structural analysis of transcription start sites of human mRNAs using full-length enriched and 5'-end enriched cDNA libraries

Unpublished (2001)

CONTACT: Yutaka Suzuki

DEPARTMENT: Department of Virology

INSTITUTE: Institute of Medical Science, University of Tokyo

ADDRESS: 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

EMAIL: ysuzuki@ims.u-tokyo.ac.jp

Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano S.

Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).

FEATURES

source

1..50

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone="HEP15388"

/clone\_ltb="Sugano Homo sapiens CDNA library"

BASE COUNT 17 a 12 c 11 g 10 t

ORIGIN

1..50

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone="HEP15388"

/clone\_ltb="Sugano Homo sapiens CDNA library"

Alignment\_scores:

Quality: 48.00 Length: 14

Ratio: 4.364 Gaps: 0

Percent Similarity: 78.571 Percent Identity: 71.429

alignment\_block:

US-09-439-311-2 x AU104260 ..

Align seg 1/1 to: AU104260 from: 1 to: 50

143 PheGlnIleGlySerSerAsnGlnThrIleTysAlaSer 156

|||||:|||||

4 TTTCAGCTTGACACTGTTCCAAATCAGACCAACGACAGC 45

seq\_name: gb\_gss:B04096

seq\_documentation\_block:

LOCUS B04096 60 bp DNA GSS 13-JUL-1996

DEFINITION CSRL-25g1-u CSRL flow sorted Chromosome 11 specific cosmid Homo

ACCESSION B04096

VERSION B04096.1 GI:1413374

KEYWORDS GSS.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 60)

Evans,G.A., Burbee,D., Davies,C., Hahner,L., Oliver,T., Gilbert,M., Jones,D., Ward,T., Gilliland,E., Schlegemann,J., Probst,S., Harris

TITLE  
JOURNAL  
COMMENT

J., DeFord, J., McFarland, J., Burzinski, K., Khan, M., Kupfer, K. and Garner, H.R.  
Genomic Sequence Sampled Map of Chromosome 11  
Unpublished (1996)  
Contact: Evans GA, Shane Probst  
Modermott Center for Human Growth and Development  
University of Texas Southwestern Medical Center At Dallas  
5323 Harry Hines Blvd, Dallas TX 75235-8591  
Tel: 214-648-1600  
Fax: 214-648-1666  
Email: gevas@utsw.swmed.edu, shane@modermott.swmed.edu

FEATURES  
source

Class: cosmid ends  
High quality sequence stop: 60.  
Location/Qualifiers  
1. 60  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="CSRL-25g1"  
/clone\_lib="CSRL flow sorted Chromosome 11 specific cosmid"  
/sex="female"  
/cell\_type="chimeric hamster somatic cell hybrid"  
/note="Vector: sCos1, Human Chromosome 11 specific cosmid library prepared from flow sorted human Chromosome 11 derived from Chinese Hamster Ovary (CHO) monochromosomal somatic cell hybrid, J1"

BASE COUNT 16 a 16 c 5 g 22 t 1 others  
ORIGIN

alignment\_scores:  
Quality: 45.00 Length: 17  
Ratio: 3.000 Gaps: 0  
Percent Similarity: 88.235 Percent Identity: 52.941

alignment\_block:  
US-09-439-311-2 x B04096 ..  
Align seg 1/1 to: B04096 from: 1 to: 60

112 TleaaaglytleuHnHstHrglsuayrgrlyargleu 128  
|||||:|||||:|||||:|||||:|||||:|||||:|||||  
4 ATTACGCTCTCATTCAGACCTCCCTTCATTTCNAATACAAATAGTT 53

128 e 128  
|  
54 C 54

seq\_name: gb\_gss:A2469793

seq\_documentation\_block:  
LOCUS A2469793 44 bp DNA GSS 04-OCT-2000  
DEFINITION LM0283FP04 Mouse 10kb plasmid UNGC1M library Mus musculus genomic  
clone UNGC1M0283FP04 R. DNA sequence.

ACCESSION A2469793  
VERSION A2469793.1 GI:10627918  
KEYWORDS GSS.  
SOURCE house mouse.  
ORGANISM Mus musculus

REFERENCE  
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 44)  
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausen, A. and Wright, D., Weiser, R.

TITLE  
JOURNAL  
COMMENT

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center  
University of Utah

FEATURES  
source

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SIC, UT 84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddun@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0283 row: F column: 04  
Seq primer: CACCAAGGAAACAGCTATGACC  
Class: plasmid ends  
High quality sequence stop: 44.  
Location/Qualifiers  
1. 44  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone\_lib="UNGCM0283FP04"  
/clone\_lib="Mouse 10kb plasmid UNGC1M library"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: pMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g114732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 9 a 12 c 12 g 11 t  
ORIGIN

alignment\_scores:  
Quality: 39.00 Length: 13  
Ratio: 3.545 Gaps: 0  
Percent Similarity: 84.615 Percent Identity: 53.846

alignment\_block:  
US-09-439-311-2 x A2469793 ..  
Align seg 1/1 to: A2469793 from: 1 to: 44

312 GtualaaglytleuHnHstHrglsuayrgrlyargleu 324  
|||||:|||||:|||||:|||||:|||||:|||||:|||||  
5 GGGGCTGGCATTGCTCTCATTCAGACACTTGTGGCAGCTTC 43

seq\_name: gb\_est1:A0107968

seq\_documentation\_block:  
LOCUS A0107968 50 bp mRNA EST 05-APR-2001  
DEFINITION A0107968 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
KRT11L118, mRNA sequence.

ACCESSION A0107968  
VERSION A0107968.1 GI:13557490  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens

REFERENCE  
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 50)  
Suzuki, Y., Tsunoda, T., Taira, H., Mizushima-Sugano, J., Sese, J., Hata, H., Ota, T., Isogai, T., Tanaka, T., Nakamura, Y., Morishita, S., Okubo, K., Suyama, A. and Sugano, S.



```

/clone="IMAGE:306076"
/clone_lib="Soares_parathyroid_tumor_NbHNA"
/russue_type="parathyroid tumor"
/dev_stage="adult"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: parathyroid gland; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site.1: Not I; Site.2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer
[5'-TGTACCAATCTGAGTGGAGCGCCGACCAATTTTTTTTTTTTTTTTTTTT
TTTTT-3'], double-stranded cDNA was size selected, ligated to Eco RI adapters (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT7T3D vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by Benito Soares and M. Fatima Bonaldi. RNA from sporadic parathyroid adenomas was kindly provided by Dr. Stephen Marx, National Institute of Diabetes and Digestive and Kidney Diseases, NIH."
BASE COUNT      8 a      7 c      19 g      14 t      4 others
ORIGIN

alignment_scores:
    Quality:      39.00      *      Length:      17
    Ratio:        3.545      *      Gaps:        0
    Percent Similarity: 64.706      Percent Identity: 47.059

alignment_block:
US-09-439-311-2 x W20078      ..

Align seg 1/1 to: W20078 from: 1 to: 52

299 AspGlyArgGlyIleIysIleThrgySerIleGlyValGlyAlaGlyI 315
:::| | | | | | | | | | | | | | | | | | | | | | | | | | |
2 AATGCTGNNAGTCTTCACACAGTACGACGCTGCTGCTGCTGCTGAT 51
315 e 315
52 T 52

seq_name: gb_gss:A2921603

seq_documentation_block:
LOCUS      A2921603      57 bp      DNA      GSS      20-MAR-2001
DEFINITION 1006030F10.x1 1006 - Rescuem Grid G zea mays genomic, DNA
sequence.
ACCESSION  A2921603
VERSION    A2921603.1 GI:13393406
KEYWORDS   GSS.
SOURCE     Zea mays.
ORGANISM  Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PAC
Clade; Panicoideae; Andropogoneae; Zea.
1 (bases 1 to 57)
Walbot.V.
Maize genomic sequences found using engineered Rescuem transposon
unpublished (2001)
Contact: Walbot V
Department of Biological Sciences
Stanford University
855 California Ave, Palo Alto, CA 94304, USA
Tel: 650 723 2227
Fax: 650 725 8221
Email: walbot@stanford.edu
Sequence was trimmed at possible ligation site. Post-ligation
sequence submitted separately.
Plate: 1006030 row: F column: 10
Class: transposon-tagged.
Location/Qualifiers
1..57
/organism="Zea mays"

```

```

/cultivar="mixed background W23/A188/B73"
/db_xref="taxon:4577"
/clone_lib="1006 - Rescuemu Grid G"
/tissue_type="leaf"
/dev_stage="adult"
/lab_host="DH10B"
/notes="Organ: leaf; Vector: Rescuemu (engineered from
pBluescript backbone); Site:1: BamHI; Site:2: BglII;
Rescuemu is a 4.9 kb, modified maize Mu transposon
designed to allow plasmid rescue from total genomic DNA.
Mu elements insert preferentially into transcription
units. For more information on Rescuemu, go to the web
site 'www.zmld.iastate.edu' and follow the links for
'Rescuemu.' Grid G was grown at Stanford in 2000. DNA was
extracted from leaf punches, double digested using BamHI
and BglII, and ligated to form circular plasmids. DH10B
cells were transformed and then screened on LB plates with
ampicillin."

BASE COUNT      13 a      18 c      7 g      19 t
ORIGIN

alignment_scores:
    Quality:      39.00      Length:      11
    Ratio:         4.333      Gaps:         0
Percent Similarity: 81.818      Percent Identity: 54.545

alignment_block:
US-09-439-311-2 x A2921603/rev ..

Align seg 1/1 to reverse of: A2921603 from: 1 to: 57
    309 IleglyvaIgaIyAlaGlytLeuHtHrGlu 319
    ::::::::::::::::::::|||
    54 CTGGGGATGAGAGTGATATCTGCACAGAG 22

seq_name: gb_gss:A2998589

seq_documentation_block:
LOCUS      A2998589      54 bp      DNA      GSS      27-APR-2001
DEFINITION  2M0285D08R Mouse 10kb plasmid UGC2M library Mus musculus genomic
clone ugc2m0285D08 R, DNA sequence.
ACCESSION  A2998589
VERSION    A2998589.1 GI:13869816
KEYWORDS   GSS.
SOURCE     house mouse.
ORGANISM   Mus musculus
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE  1 (bases 1 to 54)
AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamll,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
            ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
            and Wright,D., Weiss,R.
TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL   Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical polymers Research Bldg., 20 S. 2030 E., SLIC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0285 row: D column: 08
            Seq Primer: CACACAGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 54.
            Location/Qualifiers
            1..54
            /organism="Mus musculus"

```

```

/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UGC2M0285D08"
/clone_lib="Mouse 10kb plasmid UGC2M library"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (female) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g114732141gblaf129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT      11 a      2 c      21 g      20 t
ORIGIN

alignment_scores:
    Quality:      38.50      Length:      18
    Ratio:         2.750      Gaps:         1
Percent Similarity: 77.778      Percent Identity: 50.000

alignment_block:
US-09-439-311-2 x A2998589 ..

Align seg 1/1 to: A2998589 from: 1 to: 54
    194 AspphetylphapservAlValIleserTnserVaIGlyThrGlye 210
    ::::::::::::::::::::|||
    10 GATTATTAATTGCAATCTTGATTT.....GTGGGATGAGGGGT 50
    210 ucly 211
    :|||
    51 GGCG 54

seq_name: gb_estl:A0106648

seq_documentation_block:
LOCUS      A0106648      50 bp      mRNA      EST      05-APR-2001
DEFINITION  A0106648 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
KAT05523, mRNA sequence.
ACCESSION  A0106648
VERSION    A0106648.1 GI:13556169
KEYWORDS   EST.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  1 (bases 1 to 50)
AUTHORS   Suzuki,Y., Tsunoda,T., Talra,H., Mizushima-Sugano,J., Sese,J., Hata
            ,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S., Okubo
            ,K., Suyama,A. and Sugano,S.
TITLE     Fine structural analysis of transcription start sites of human
            mRNAs using full-length enriched and 5'-end enriched cDNA libraries
            Unpublished (2001)
            Contact: Yutaka Suzuki
            Department of Virology
            Institute of Medical Science, University of Tokyo
            4-6-1, Shirokane-dai, Minatoku, Tokyo 108-8639, Japan
            Email: yusuzuki@ims.u-tokyo.ac.jp
            Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano

```

,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).

# FEATURES

Location/Qualifiers  
1..50  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_1lb="KAT05523"

BASE COUNT 10 a 20 c 8 g 12 t  
ORIGIN

## alignment\_scores:

Quality: 38.00 Length: 16  
Ratio: 3.455 Gaps: 0  
Percent Similarity: 68.750 Percent Identity: 56.250

## alignment\_block:

US-09-439-311-2 x AU106648/rev ..

Align seg 1/1 to reverse of: AU106648 from: 1 to: 50

247 GlnAaphaAlaIleasnGlyValIleGlyLysValAspTyrSer 262

49 CAGGCTGCAGCTGTGTCTCAGTACAGTCAAGGGGAGTATTCG 2

seq\_name: gb\_est2:C20861

seq\_documentation\_block:

LOCUS C20861 56 bp mRNA EST 23-OCT-1996  
DEFINITION HUMGS0004926 Human adult (K.Okubo) Homo sapiens cDNA 3', mRNA  
sequence.

ACCESSION C20861  
VERSION C20861.1 GI:1621971  
KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1 (bases 1 to 56)

AUTHORS Okubo,K.

TITLE BodyMap: human gene expression database

JOURNAL Unpublished (1995)

COMMENT Contact: Okubo,K.

Institute for Molecular and Cellular Biol

Osaka University  
1-3,Yamada-oka, Suita, Osaka Pref. 565, Japan

Tel: 06-877-5111(ex.3315)

Email: kousaku@imcb.osaka-u.ac.jp

Human Gene Signature, 3'-directed cDNA sequence. We are not

submitting the same cDNA sequence redundantly to DBJ since 1993.

For the abundance information of clones with this sequence in this

library and as well as in other 3'-directed libraries, see

http://www.imcb.osaka-u.ac.jp/bodymap/. The sequences of the clones

represented by this GS sequences is also found there.

## FEATURES

source

1..56

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone\_1lb="Human adult (K.Okubo)"

/dev\_stage="adult"

BASE COUNT 19 a 9 c 7 g 19 t 2 others

ORIGIN

alignment\_scores:

Quality: 38.00 Length: 18

Ratio: 2.923 Gaps: 0

Percent Similarity: 72.222 Percent Identity: 44.444

alignment\_block:

US-09-439-311-2 x C20861/rev ..

Align seg 1/1 to reverse of: C20861 from: 1 to: 56

215 GluGluIleAsnArgAsnAlaAspLysThrGlyIleArgAlaThrPheAs 231

54 GAACAGATATATCTTCTAATACAGTTGTCTCATAGATTCTNNTTGA 5

231 pval 232

4 GATC 1

seq\_name: gb\_gss:A2654882

seq\_documentation\_block:

LOCUS A2654882 57 bp DNA GSS 14-DEC-2000  
DEFINITION 1M0529N2F Mouse 10kb plasmid UUGCIM library Mus musculus genomic  
clone UUGCIM0529N2 F, DNA sequence.

ACCESSION A2654882  
VERSION A2654882.1 GI:11792028

KEYWORDS GSS.

SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

University of Utah Genome Center  
University of Utah  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0529 row: N column: 22

Seq primer: CGTTGTAAACGACGCCAGCT

Class: plasmid ends

High quality sequence stop: 57.

Location/Qualifiers

1..57

/organism="Mus musculus"

/strain="C57BL/6J"

/db\_xref="taxon:10090"

/clone="UUGCIM0529N2"

/clone\_1lb="Mouse 10kb plasmid UUGCIM library"

/sex="Male"

/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PMD42nv; Purified genomic DNA from M.  
musculus C57BL/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adapted DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of PMD42 (g114732114[gb|AF129072.1]), a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adapted mouse DNA was annealed to  
adapted vector DNA, and transformed into  
chemically-competent E. coli XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."

BASE COUNT 16 a 23 c

6 g 12 t



constructed by Dr. Sumio Sugano (University of Tokyo)

seq\_name: gb\_est1:AU102739

seq\_documentation\_block:

LOCUS AU102739 50 bp mRNA EST 05-APR-2001

DEFINITION AU102739 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone

HRC13119, mRNA sequence.

ACCESSION AU102739

VERSION AU102739.1 GI:13552260

KEYWORDS EST.

SOURCE human.

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 50)

Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Hata

,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S., Okubo

,K., Suyama,A. and Sugano,S.

Fine structural analysis of transcription start sites of human

mRNAs using full-length enriched and 5'-end enriched cDNA libraries

Unpublished (2001)

COMMENT

Contact: Yutaka Suzuki

Department of Virology

Institute of Medical Science, University of Tokyo

4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

Email: ysuzuki@ims.u-tokyo.ac.jp

Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano

,S. Construction and characterization of a full length-enriched and

a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).

location/Qualifiers

1..50

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone\_lib="HRC13119"

/clone\_lib="Sugano Homo sapiens cDNA library"

BASE COUNT 7 a 16 c 18 g 9 t

ORIGIN

alignment\_scores:

Quality: 37.00 Length: 14

Ratio: 2.846 Gaps: 0

Percent Similarity: 92.857 Percent Identity: 50.000

alignment\_block:

US-09-439-311-2 x AU102739/rev ..

Align seg 1/1 to reverse of: AU102739 from: 1 to: 50

93 ThrglnAlaAlaGlnAspGlyGlnSerLeuLysThrArgThr 106

|||||:|||||:|||||:|||||:|||||:|||||:|||||

42 ACTAGGCGCGCGCTACAGGAGCTCATTTCTCCCGCACG 1